Appendix 16b: Forest plots for clinical evidence reviews on pharmacological interventions

SSRIs (OCD, adults); Clomipramine (OCD, adults); TCAs (OCD); SNRIs (OCD); MAOIs (OCD); Anxiolytics (OCD); Other Pharmacological (OCD); Augmentation (OCD); SSRIs (OCD, children); Clomipramine (OCD, children); Pharmacological (BDD)

SSRIs (OCD, adults)



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 02 Serious adverse events



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 03 Suicide attempts




Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 04 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram
Montgomery 2001 46/300 17/101 0.91 [0.55, 1.51]
Subtotal (95% CI) 300 101 0.91 [0.55, 1.51]
Total events: 46 (SSRI), 17 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
02 Fluoxetine
Jenike 1997 4/23 3/21 1.22 [0.31, 4.82]
Montgomery 1993 41/160 15/57 0.97 [0.59, 1.62]
Subtotal (95% CI) 183 78 1.00 [0.62, 1.62]
Total events: 45 (SSRI), 18 (Placebo)
Test for heterogeneity: Chi² = 0.09, df = 1 (P = 0.76), I² = 0%
Test for overall effect: Z = 0.02 (P = 0.99)
03 Fluvoxamine
Goodman 1989 2/23 6/23 0.33 [0.07, 1.48]
Goodman 1996 23/80 17/80 1.35 [0.78, 2.33]
Hollander 2003b 43/127 31/126 1.38 [0.93, 2.03]
Jenike 1990a 0/18 0/20 Not estimable
Mallya 1992 5/19 6/20 0.88 [0.32, 2.40]
Perse 1987 1/10 1/10 1.00 [0.07, 13.87]
Subtotal (95% CI) 277 279 1.21 [0.91, 1.62]
Total events: 74 (SSRI), 61 (Placebo)
Test for heterogeneity: Chi² = 3.85, df = 4 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.30 (P = 0.19)
04 Paroxetine
Burnham 1993 28/82 20/77 1.31 [0.81, 2.13]
Hollander 2003d 53/259 15/89 1.21 [0.72, 2.04]
Zohar 1996a 49/201 39/99 0.62 [0.44, 0.87]
Subtotal (95% CI) 542 265 0.91 [0.71, 1.16]
Total events: 130 (SSRI), 74 (Placebo)
Test for heterogeneity: Chi² = 8.21, df = 2 (P = 0.02), I² = 75.6%
Test for overall effect: Z = 0.76 (P = 0.45)
05 Sertraline
Chouinard 1990 3/43 7/44 0.44 [0.12, 1.59]
Greist 1995a 65/241 24/84 0.94 [0.63, 1.40]
Jenike 1990b 0/10 0/9 Not estimable
Kronig 1999 25/86 25/81 0.94 [0.59, 1.50]
Subtotal (95% CI) 380 218 0.89 [0.67, 1.20]
Total events: 93 (SSRI), 56 (Placebo)
Test for heterogeneity: Chi² = 1.30, df = 2 (P = 0.52), I² = 0%
Test for overall effect: Z = 0.76 (P = 0.44)
Total (95% CI) 1682 941 0.98 [0.85, 1.13]
Total events: 388 (SSRI), 226 (Placebo)
Test for heterogeneity: Chi² = 16.94, df = 13 (P = 0.20), I² = 23.3%
Test for overall effect: Z = 0.26 (P = 0.79)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours placebo

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 05 Leaving study early due to adverse events




Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 06 Non-responders (OCD) (CGI or Y-BOCS)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram
Montgomery 2001 126/300 64/101 0.66 [0.54, 0.81]
Subtotal (95% CI) 300 101 0.66 [0.54, 0.81]
Total events: 126 (SSRI), 64 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.05 (P < 0.0001)
02 Fluoxetine
Beasley 1992 190/266 82/89 0.78 [0.70, 0.85]
Montgomery 1993 92/160 46/57 0.71 [0.59, 0.86]
Subtotal (95% CI) 426 146 0.75 [0.69, 0.82]
Total events: 282 (SSRI), 128 (Placebo)
Test for heterogeneity: Chi² = 0.69, df = 1 (P = 0.41), I² = 0%
Test for overall effect: Z = 6.18 (P < 0.00001)
03 Fluvoxamine
Hollander 2003b 74/127 90/126 0.82 [0.68, 0.98]
Mallya 1992 13/19 19/20 0.72 [0.52, 0.99]
Subtotal (95% CI) 146 146 0.80 [0.68, 0.94]
Total events: 87 (SSRI), 109 (Placebo)
Test for heterogeneity: Chi² = 0.45, df = 1 (P = 0.50), I² = 0%
Test for overall effect: Z = 2.69 (P = 0.007)
04 Paroxetine
Burnham 1993 47/82 45/77 0.98 [0.75, 1.28]
Hollander 2003d 161/259 65/89 0.85 [0.73, 1.00]
Kamijima 2004 48/95 74/96 0.66 [0.52, 0.82]
Zohar 1996a 92/201 64/99 0.71 [0.57, 0.87]
Subtotal (95% CI) 637 361 0.78 [0.71, 0.87]
Total events: 348 (SSRI), 248 (Placebo)
Test for heterogeneity: Chi² = 7.09, df = 3 (P = 0.07), I² = 57.7%
Test for overall effect: Z = 4.66 (P < 0.00001)
05 Sertraline
Greist 1995a 148/241 59/84 0.87 [0.74, 1.04]
Subtotal (95% CI) 241 84 0.87 [0.74, 1.04]
Total events: 148 (SSRI), 59 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1750 838 0.77 [0.73, 0.82]
Total events: 991 (SSRI), 608 (Placebo)
Test for heterogeneity: Chi² = 12.76, df = 9 (P = 0.17), I² = 29.5%
Test for overall effect: Z = 8.51 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 07 Non-responders (MDD)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine
Goodman 1989 18/23 20/23 0.90 [0.69, 1.18]
Subtotal (95% CI) 23 23 0.90 [0.69, 1.18]
Total events: 18 (SSRI), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 08 Non-remitters
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine
Hollander 2003b 106/127 117/126 0.90 [0.82, 0.98]
Subtotal (95% CI) 127 126 0.90 [0.82, 0.98]
Total events: 106 (SSRI), 117 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.02)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 09 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Citalopram
Montgomery 2001 102 -8.40(7.30) 101 -5.60(6.90) -0.39 [-0.67, -0.11]
Subtotal (95% CI) 102 101 -0.39 [-0.67, -0.11]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.006)
02 Fluoxetine
Beasley 1992 75 18.90(8.30) 76 23.60(7.50) -0.59 [-0.92, -0.27]
Jenike 1997 19 16.20(6.30) 18 18.70(6.10) -0.39 [-1.05, 0.26]
Montgomery 1993 52 -5.13(6.41) 56 -3.70(5.98) -0.23 [-0.61, 0.15]
Subtotal (95% CI) 146 150 -0.43 [-0.66, -0.20]
Test for heterogeneity: Chi² = 2.03, df = 2 (P = 0.36), I² = 1.5%
Test for overall effect: Z = 3.66 (P = 0.0002)
03 Fluvoxamine
Goodman 1989 21 19.40(7.00) 21 28.00(7.00) -1.21 [-1.87, -0.54]
Goodman 1996 78 -3.95(6.28) 78 -1.71(4.88) -0.40 [-0.71, -0.08]
Hollander 2003b 117 -8.50(7.57) 120 -5.60(7.67) -0.38 [-0.64, -0.12]
Jenike 1990a 18 18.80(4.00) 20 21.80(7.60) -0.48 [-1.12, 0.17]
Subtotal (95% CI) 234 239 -0.46 [-0.64, -0.27]
Test for heterogeneity: Chi² = 5.39, df = 3 (P = 0.15), I² = 44.4%
Test for overall effect: Z = 4.88 (P < 0.00001)
04 Paroxetine
Burnham 1993 79 -5.61(7.47) 75 -4.60(7.53) -0.13 [-0.45, 0.18]
Kamijima 2004 94 -8.11(8.00) 94 -3.46(6.10) -0.65 [-0.94, -0.36]
Zohar 1996a 198 -8.00(8.00) 99 -5.00(7.90) -0.38 [-0.62, -0.13]
Subtotal (95% CI) 371 268 -0.40 [-0.56, -0.23]
Test for heterogeneity: Chi² = 5.56, df = 2 (P = 0.06), I² = 64.0%
Test for overall effect: Z = 4.82 (P < 0.00001)
05 Sertraline
Jenike 1990b 10 20.60(9.20) 8 22.30(7.80) -0.19 [-1.12, 0.74]
Subtotal (95% CI) 10 8 -0.19 [-1.12, 0.74]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 863 766 -0.42 [-0.52, -0.32]
Test for heterogeneity: Chi² = 13.50, df = 11 (P = 0.26), I² = 18.5%
Test for overall effect: Z = 8.23 (P < 0.00001)
-4 -2 0 2 4
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 10 NIMH-OC
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram
Montgomery 2001 102 -2.80(2.50) 101 -1.80(2.30) -0.41 [-0.69, -0.14]
Subtotal (95% CI) 102 101 -0.41 [-0.69, -0.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.003)
02 Fluoxetine
Jenike 1997 19 7.00(1.10) 18 7.20(1.30) -0.16 [-0.81, 0.48]
Subtotal (95% CI) 19 18 -0.16 [-0.81, 0.48]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
03 Fluvoxamine
Goodman 1996 78 -1.32(2.25) 78 -0.40(1.78) -0.45 [-0.77, -0.13]
Jenike 1990a 18 6.80(1.20) 20 8.00(2.20) -0.65 [-1.31, 0.00]
Subtotal (95% CI) 96 98 -0.49 [-0.78, -0.20]
Test for heterogeneity: Chi² = 0.30, df = 1 (P = 0.59), I² = 0%
Test for overall effect: Z = 3.36 (P = 0.0008)
04 Paroxetine
Burnham 1993 79 -1.42(2.04) 75 -1.04(2.08) -0.18 [-0.50, 0.13]
Zohar 1996a 198 -2.50(2.90) 99 -1.40(2.90) -0.38 [-0.62, -0.14]
Subtotal (95% CI) 277 174 -0.31 [-0.50, -0.11]
Test for heterogeneity: Chi² = 0.91, df = 1 (P = 0.34), I² = 0%
Test for overall effect: Z = 3.11 (P = 0.002)
05 Sertraline
Jenike 1990b 10 8.20(2.00) 9 9.30(2.50) -0.47 [-1.38, 0.45]
Subtotal (95% CI) 10 9 -0.47 [-1.38, 0.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 504 400 -0.37 [-0.50, -0.23]
Test for heterogeneity: Chi² = 2.84, df = 6 (P = 0.83), I² = 0%
Test for overall effect: Z = 5.39 (P < 0.00001)
-4 -2 0 2 4
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 11 General Rating Scale: compulsions
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 3.56(2.00) 8 5.12(2.00) -0.74 [-1.76, 0.29]
Subtotal (95% CI) 8 8 -0.74 [-1.76, 0.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 12 General Rating Scale: obsessions
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 3.07(1.98) 8 4.31(2.67) -0.50 [-1.50, 0.50]
Subtotal (95% CI) 8 8 -0.50 [-1.50, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 13 Maudsley Obsessive Compulsive Inventory
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 13.87(5.32) 8 16.12(4.59) -0.43 [-1.42, 0.57]
Subtotal (95% CI) 8 8 -0.43 [-1.42, 0.57]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-10 -5 0 5 10
Favours SSRI Favours placebo

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 14 Obsessive-Compulsive Checklist

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluvoxamine						
Perse 1987	8	20.06(12.92)	8	26.19(13.88)		-0.43 [-1.43, 0.56]
Subtotal (95% CI)	8		8			-0.43 [-1.43, 0.56]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.85 (P = 0.39)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 15 OCD Scale (CPRS)

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Jenike 1997	19	6.70(2.60)	18	5.80(3.30)		0.30 [-0.35, 0.95]
Subtotal (95% CI)	19		18			0.30 [-0.35, 0.95]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.90 (P = 0.37)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 16 Beck Depression Inventory

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluvoxamine						
Perse 1987	8	9.73(7.51)	8	12.37(7.56)		-0.33 [-1.32, 0.66]
Subtotal (95% CI)	8		8			-0.33 [-1.32, 0.66]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.66 (P = 0.51)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 17 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Montgomery 1993	52	-1.85(6.04)	56	-1.34(6.92)		-0.08 [-0.46, 0.30]
Subtotal (95% CI)	52		56			-0.08 [-0.46, 0.30]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.40 (P = 0.69)						
02 Fluvoxamine						
Perse 1987	8	9.47(5.55)	8	12.93(5.02)		-0.62 [-1.63, 0.39]
Subtotal (95% CI)	8		8			-0.62 [-1.63, 0.39]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.20 (P = 0.23)						
Total (95% CI)	60		64			-0.14 [-0.50, 0.21]
Test for heterogeneity: Chi² = 0.96, df = 1 (P = 0.33), I² = 0%						
Test for overall effect: Z = 0.80 (P = 0.42)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 18 Montgomery-Asberg Depression Rating Scale

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Citalopram						
Montgomery 2001	102	-3.40(6.30)	101	-1.30(6.70)		-0.32 [-0.60, -0.04]
Subtotal (95% CI)	102		101			-0.32 [-0.60, -0.04]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.28 (P = 0.02)						
02 Fluoxetine						
Montgomery 1993	52	-2.96(8.09)	56	-2.88(9.27)		-0.01 [-0.39, 0.37]
Subtotal (95% CI)	52		56			-0.01 [-0.39, 0.37]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.05 (P = 0.96)						
03 Paroxetine						
Zohar 1996a	198	-3.40(7.90)	99	-0.60(7.90)		-0.35 [-0.60, -0.11]
Subtotal (95% CI)	198		99			-0.35 [-0.60, -0.11]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.85 (P = 0.004)						
Total (95% CI)	352		256			-0.28 [-0.44, -0.11]
Test for heterogeneity: Chi² = 2.42, df = 2 (P = 0.30), I² = 17.2%						
Test for overall effect: Z = 3.30 (P = 0.0010)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 19 Hamilton Anxiety Scale

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluvoxamine						
Perse 1987	8	7.69(3.60)	8	12.37(7.56)		-0.75 [-1.77, 0.28]
Subtotal (95% CI)	8		8			-0.75 [-1.77, 0.28]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.43 (P = 0.15)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 20 Clinical Global Impression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Jenike 1997	19	3.10(1.00)	18	3.20(1.00)		-0.10 [-0.74, 0.55]
Subtotal (95% CI)	19		18			-0.10 [-0.74, 0.55]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.30 (P = 0.77)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 21 Clinical Global Impressions: severity

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Paroxetine						
Zohar 1996a	194	-1.20(1.40)	99	-0.70(1.30)		-0.36 [-0.61, -0.12]
Subtotal (95% CI)	194		99			-0.36 [-0.61, -0.12]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.93 (P = 0.003)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 22 Sheehan Disability Scale: family

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Citalopram						
Montgomery 2001	102	-1.80(2.40)	101	-1.00(2.40)		-0.33 [-0.61, -0.06]
Subtotal (95% CI)	102		101			-0.33 [-0.61, -0.06]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.35 (P = 0.02)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 23 Sheehan Disability Scale: social

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Citalopram						
Montgomery 2001	102	-2.00(2.20)	101	-1.30(2.00)		-0.33 [-0.61, -0.05]
Subtotal (95% CI)	102		101			-0.33 [-0.61, -0.05]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.35 (P = 0.02)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 24 Sheehan Disability Scale: work

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Citalopram						
Montgomery 2001	102	-1.90(2.40)	101	-1.10(2.10)		-0.35 [-0.63, -0.08]
Subtotal (95% CI)	102		101			-0.35 [-0.63, -0.08]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.50 (P = 0.01)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 25 Symptom Checklist-90

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Paroxetine						
Zohar 1996a	169	-29.00(47.10)	77	-19.50(37.30)		-0.21 [-0.48, 0.06]
Subtotal (95% CI)	169		77			-0.21 [-0.48, 0.06]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.55 (P = 0.12)						

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 26 Subanalysis: Y-BOCS in patients with comorbid depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
02 Fluoxetine						
Beasley 1992	75	18.90(8.30)	76	23.60(7.50)		-0.59 [-0.92, -0.27]
Montgomery 1993	52	-5.13(6.41)	56	-3.70(5.98)		-0.23 [-0.61, 0.15]
Subtotal (95% CI)	127		132			-0.44 [-0.68, -0.19]
Test for heterogeneity: Chi² = 2.02, df = 1 (P = 0.16), I² = 50.4%						
Test for overall effect: Z = 3.47 (P = 0.0005)						
03 Fluvoxamine						
Goodman 1989	21	19.40(7.00)	21	28.00(7.00)		-1.21 [-1.87, -0.54]
Subtotal (95% CI)	21		21			-1.21 [-1.87, -0.54]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 3.56 (P = 0.0004)						
04 Paroxetine						
Kamijima 2004	94	-8.11(8.00)	94	-3.46(6.10)		-0.65 [-0.94, -0.36]
Subtotal (95% CI)	94		94			-0.65 [-0.94, -0.36]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 4.35 (P < 0.0001)						
Total (95% CI)	242		247			-0.58 [-0.76, -0.40]
Test for heterogeneity: Chi² = 6.94, df = 3 (P = 0.07), I² = 56.8%						
Test for overall effect: Z = 6.22 (P < 0.00001)						




Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 27 Subanalysis: Non-responders (OCD) (CGI or Y-BOCS) in patients with comorbid depression
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
02 Fluoxetine
Beasley 1992 190/266 82/89 0.78 [0.70, 0.85]
Montgomery 1993 92/160 46/57 0.71 [0.59, 0.86]
Subtotal (95% CI) 426 146 0.75 [0.69, 0.82]
Total events: 282 (SSRI), 128 (Placebo)
Test for heterogeneity: Chi² = 0.69, df = 1 (P = 0.41), I² = 0%
Test for overall effect: Z = 6.18 (P < 0.00001)
04 Paroxetine
Kamijima 2004 48/95 74/96 0.66 [0.52, 0.82]
Subtotal (95% CI) 95 96 0.66 [0.52, 0.82]
Total events: 48 (SSRI), 74 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.0003)
Total (95% CI) 521 242 0.73 [0.66, 0.79]
Total events: 330 (SSRI), 202 (Placebo)
Test for heterogeneity: Chi² = 2.58, df = 2 (P = 0.28), I² = 22.4%
Test for overall effect: Z = 7.03 (P < 0.00001)
0.5
0.7
1
1.5
2
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 01 Adverse events
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 67/98 74/102 0.94 [0.79, 1.13]
Subtotal (95% CI) 98 102 0.94 [0.79, 1.13]
Total events: 67 (Dose 1), 74 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 72/100 74/102 0.99 [0.84, 1.18]
Subtotal (95% CI) 100 102 0.99 [0.84, 1.18]
Total events: 72 (Dose 1), 74 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 72/100 67/98 1.05 [0.88, 1.26]
Subtotal (95% CI) 100 98 1.05 [0.88, 1.26]
Total events: 72 (Dose 1), 67 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
04 Sertraline rapid titration vs slow titration
Bogetto 2002 13/17 11/15 1.04 [0.70, 1.56]
Subtotal (95% CI) 17 15 1.04 [0.70, 1.56]
Total events: 13 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
0.5
0.7
1
1.5
2
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 02 Leaving study early
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 15/98 16/102 0.98 [0.51, 1.86]
Subtotal (95% CI) 98 102 0.98 [0.51, 1.86]
Total events: 15 (Dose 1), 16 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 15/100 16/102 0.96 [0.50, 1.83]
Subtotal (95% CI) 100 102 0.96 [0.50, 1.83]
Total events: 15 (Dose 1), 16 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 15/100 15/98 0.98 [0.51, 1.89]
Subtotal (95% CI) 100 98 0.98 [0.51, 1.89]
Total events: 15 (Dose 1), 15 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Montgomery 1993 13/52 14/53 0.95 [0.49, 1.81]
Subtotal (95% CI) 52 53 0.95 [0.49, 1.81]
Total events: 13 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Montgomery 1993 14/55 14/53 0.96 [0.51, 1.82]
Subtotal (95% CI) 55 53 0.96 [0.51, 1.82]
Total events: 14 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Montgomery 1993 14/55 13/52 1.02 [0.53, 1.96]
Subtotal (95% CI) 55 52 1.02 [0.53, 1.96]
Total events: 14 (Dose 1), 13 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
07 Paroxetine 40mg vs Paroxetine 20mg
Hollander 2003d 20/86 14/88 1.46 [0.79, 2.70]
Subtotal (95% CI) 86 88 1.46 [0.79, 2.70]
Total events: 20 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
08 Paroxetine 60mg vs Paroxetine 20mg
Hollander 2003d 19/85 14/88 1.41 [0.75, 2.62]
Subtotal (95% CI) 85 88 1.41 [0.75, 2.62]
Total events: 19 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
09 Paroxetine 60mg vs Paroxetine 40mg
Hollander 2003d 19/85 20/86 0.96 [0.55, 1.67]
Subtotal (95% CI) 85 86 0.96 [0.55, 1.67]
Total events: 19 (Dose 1), 20 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
10 Sertraline 100mg vs Sertraline 50mg
Greist 1995a 27/81 17/80 1.57 [0.93, 2.64]
Subtotal (95% CI) 81 80 1.57 [0.93, 2.64]
Total events: 27 (Dose 1), 17 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.09)
11 Sertraline 200mg vs Sertraline 50mg
Greist 1995a 21/80 17/80 1.24 [0.71, 2.16]
Subtotal (95% CI) 80 80 1.24 [0.71, 2.16]
Total events: 21 (Dose 1), 17 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
12 Sertraline 200mg vs Sertraline 100mg
Greist 1995a 21/80 27/81 0.79 [0.49, 1.27]
Subtotal (95% CI) 80 81 0.79 [0.49, 1.27]
Total events: 21 (Dose 1), 27 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
13 Sertraline rapid titration vs slow titration
Bogetto 2002 3/17 2/15 1.32 [0.25, 6.88]
Subtotal (95% CI) 17 15 1.32 [0.25, 6.88]
Total events: 3 (Dose 1), 2 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 03 Leaving study early due to adverse events
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 6/98 4/102 1.56 [0.45, 5.36]
Subtotal (95% CI) 98 102 1.56 [0.45, 5.36]
Total events: 6 (Dose 1), 4 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 4/100 4/102 1.02 [0.26, 3.97]
Subtotal (95% CI) 100 102 1.02 [0.26, 3.97]
Total events: 4 (Dose 1), 4 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 4/100 6/98 0.65 [0.19, 2.24]
Subtotal (95% CI) 100 98 0.65 [0.19, 2.24]
Total events: 4 (Dose 1), 6 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Beasley 1992 12/89 30/87 0.39 [0.21, 0.71]
Montgomery 1993 2/52 4/53 0.51 [0.10, 2.66]
Subtotal (95% CI) 141 140 0.40 [0.23, 0.71]
Total events: 14 (Dose 1), 34 (Dose 2)
Test for heterogeneity: Chi² = 0.09, df = 1 (P = 0.77), I² = 0%
Test for overall effect: Z = 3.14 (P = 0.002)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Beasley 1992 17/90 30/87 0.55 [0.33, 0.92]
Montgomery 1993 1/55 4/53 0.24 [0.03, 2.09]
Subtotal (95% CI) 145 140 0.51 [0.31, 0.85]
Total events: 18 (Dose 1), 34 (Dose 2)
Test for heterogeneity: Chi² = 0.53, df = 1 (P = 0.46), I² = 0%
Test for overall effect: Z = 2.61 (P = 0.009)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Beasley 1992 17/90 12/89 1.40 [0.71, 2.76]
Montgomery 1993 1/55 2/52 0.47 [0.04, 5.06]
Subtotal (95% CI) 145 141 1.27 [0.66, 2.41]
Total events: 18 (Dose 1), 14 (Dose 2)
Test for heterogeneity: Chi² = 0.75, df = 1 (P = 0.39), I² = 0%
Test for overall effect: Z = 0.72 (P = 0.47)
07 Paroxetine 40mg vs Paroxetine 20mg
Hollander 2003d 8/86 9/88 0.91 [0.37, 2.25]
Subtotal (95% CI) 86 88 0.91 [0.37, 2.25]
Total events: 8 (Dose 1), 9 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
08 Paroxetine 60mg vs Paroxetine 20mg
Hollander 2003d 12/85 9/88 1.38 [0.61, 3.11]
Subtotal (95% CI) 85 88 1.38 [0.61, 3.11]
Total events: 12 (Dose 1), 9 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
09 Paroxetine 60mg vs Paroxetine 40mg
Hollander 2003d 12/85 8/86 1.52 [0.65, 3.53]
Subtotal (95% CI) 85 86 1.52 [0.65, 3.53]
Total events: 12 (Dose 1), 8 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
10 Sertraline 100mg vs Sertraline 50mg
Greist 1995a 11/81 6/80 1.81 [0.70, 4.66]
Subtotal (95% CI) 81 80 1.81 [0.70, 4.66]
Total events: 11 (Dose 1), 6 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
11 Sertraline 200mg vs Sertraline 50mg
Greist 1995a 6/80 6/80 1.00 [0.34, 2.97]
Subtotal (95% CI) 80 80 1.00 [0.34, 2.97]
Total events: 6 (Dose 1), 6 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
12 Sertraline 200mg vs Sertraline 100mg
Greist 1995a 6/80 11/81 0.55 [0.21, 1.42]
Subtotal (95% CI) 80 81 0.55 [0.21, 1.42]
Total events: 6 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
13 Sertraline rapid titration vs slow titration
Bogetto 2002 2/17 2/15 0.88 [0.14, 5.52]
Subtotal (95% CI) 17 15 0.88 [0.14, 5.52]
Total events: 2 (Dose 1), 2 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1
Favours Dose 2

Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 04 Non-responders




Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 05 Y-BOCS
Study or sub-category | N | Dose 1 Mean (SD) | N | Dose 2 Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 98 -8.90(7.00) 102 -8.40(7.30) -0.07 [-0.35, 0.21]
Subtotal (95% CI) 98 102 -0.07 [-0.35, 0.21]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 100 -10.40(6.90) 102 -8.40(7.30) -0.28 [-0.56, 0.00]
Subtotal (95% CI) 100 102 -0.28 [-0.56, 0.00]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.05)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 100 -10.40(6.90) 98 -8.90(7.00) -0.22 [-0.49, 0.06]
Subtotal (95% CI) 100 98 -0.22 [-0.49, 0.06]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Beasley 1992 67 18.10(7.90) 75 18.90(8.30) -0.10 [-0.43, 0.23]
Montgomery 1993 52 -4.76(6.89) 52 -5.13(6.41) 0.06 [-0.33, 0.44]
Subtotal (95% CI) 119 127 -0.03 [-0.28, 0.22]
Test for heterogeneity: Chi² = 0.35, df = 1 (P = 0.55), I² = 0%
Test for overall effect: Z = 0.26 (P = 0.80)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Beasley 1992 68 16.80(7.80) 75 18.90(8.30) -0.26 [-0.59, 0.07]
Montgomery 1993 54 -6.07(6.92) 52 -5.13(6.41) -0.14 [-0.52, 0.24]
Subtotal (95% CI) 122 127 -0.21 [-0.46, 0.04]
Test for heterogeneity: Chi² = 0.21, df = 1 (P = 0.64), I² = 0%
Test for overall effect: Z = 1.63 (P = 0.10)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Beasley 1992 68 16.80(7.80) 67 18.10(7.90) -0.16 [-0.50, 0.17]
Montgomery 1993 54 -6.07(6.92) 52 -4.76(6.89) -0.19 [-0.57, 0.19]
Subtotal (95% CI) 122 119 -0.18 [-0.43, 0.08]
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.93), I² = 0%
Test for overall effect: Z = 1.36 (P = 0.18)
07 Sertraline rapid titration vs slow titration
Bogetto 2002 14 12.43(3.78) 13 13.54(4.03) -0.28 [-1.03, 0.48]
Subtotal (95% CI) 14 13 -0.28 [-1.03, 0.48]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
-4 -2 0 2 4
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 06 NIMH-OC
Study or sub-category | N | Dose 1 Mean (SD) | N | Dose 2 Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 98 -2.90(2.80) 102 -2.80(2.50) -0.04 [-0.31, 0.24]
Subtotal (95% CI) 98 102 -0.04 [-0.31, 0.24]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 100 -3.10(2.60) 102 -2.80(2.50) -0.12 [-0.39, 0.16]
Subtotal (95% CI) 100 102 -0.12 [-0.39, 0.16]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 100 -3.10(2.60) 98 -2.90(2.80) -0.07 [-0.35, 0.20]
Subtotal (95% CI) 100 98 -0.07 [-0.35, 0.20]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
-1 -0.5 0 0.5 1
Favours Dose 1 Favours Dose 2

Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 07 Hamilton Rating Scale for Depression



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 08 Montgomery-Asberg Depression Rating Scale



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 09 Sheehan Disability Score: family

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg					
Montgomery 2001	98	-2.10(2.30)	102	-1.80(2.40)	-0.13 [-0.40, 0.15]
Subtotal (95% CI)	98		102		-0.13 [-0.40, 0.15]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 0.90 (P = 0.37)					
02 Citalopram 60mg vs Citalopram 20mg					
Montgomery 2001	100	-2.30(2.40)	102	-1.80(2.40)	-0.21 [-0.48, 0.07]
Subtotal (95% CI)	100		102		-0.21 [-0.48, 0.07]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 1.47 (P = 0.14)					
03 Citalopram 60mg vs Citalopram 40mg					
Montgomery 2001	100	-2.30(2.40)	98	-2.10(2.30)	-0.08 [-0.36, 0.19]
Subtotal (95% CI)	100		98		-0.08 [-0.36, 0.19]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 0.60 (P = 0.55)					



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 10 Sheehan Disability Score: social

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg					
Montgomery 2001	98	-1.90(2.30)	102	-2.00(2.20)	0.04 [-0.23, 0.32]
Subtotal (95% CI)	98		102		0.04 [-0.23, 0.32]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 0.31 (P = 0.75)					
02 Citalopram 60mg vs Citalopram 20mg					
Montgomery 2001	100	-2.40(2.50)	102	-2.00(2.20)	-0.17 [-0.45, 0.11]
Subtotal (95% CI)	100		102		-0.17 [-0.45, 0.11]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 1.20 (P = 0.23)					
03 Citalopram 60mg vs Citalopram 40mg					
Montgomery 2001	100	-2.40(2.50)	98	-1.90(2.30)	-0.21 [-0.49, 0.07]
Subtotal (95% CI)	100		98		-0.21 [-0.49, 0.07]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 1.45 (P = 0.15)					



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 11 Sheehan Disability Score: work

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg					
Montgomery 2001	98	-2.10(2.30)	102	-1.90(2.40)	-0.08 [-0.36, 0.19]
Subtotal (95% CI)	98		102		-0.08 [-0.36, 0.19]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 0.60 (P = 0.55)					
02 Citalopram 60mg vs Citalopram 20mg					
Montgomery 2001	100	-2.00(2.50)	102	-1.90(2.40)	-0.04 [-0.32, 0.24]
Subtotal (95% CI)	100		102		-0.04 [-0.32, 0.24]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 0.29 (P = 0.77)					
03 Citalopram 60mg vs Citalopram 40mg					
Montgomery 2001	100	-2.00(2.50)	98	-2.10(2.30)	0.04 [-0.24, 0.32]
Subtotal (95% CI)	100		98		0.04 [-0.24, 0.32]
Test for heterogeneity: not applicable					
Test for overall effect: Z = 0.29 (P = 0.77)					




Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 01 Leaving study early
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram vs Fluvoxamine
Mundo 1997a 0/11 0/10 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Citalopram vs Paroxetine
Mundo 1997a 0/11 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 Fluoxetine vs Sertraline
Bergeron 2002 22/73 22/77 1.05 [0.64, 1.73]
Subtotal (95% CI) 73 77 1.05 [0.64, 1.73]
Total events: 22 (SSRI 1), 22 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 0/10 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.5 0.7 1 1.5 2
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram vs Fluvoxamine
Mundo 1997a 0/11 0/10 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Citalopram vs Paroxetine
Mundo 1997a 0/11 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 Fluoxetine vs Sertraline
Bergeron 2002 10/73 15/77 0.70 [0.34, 1.46]
Subtotal (95% CI) 73 77 0.70 [0.34, 1.46]
Total events: 10 (SSRI 1), 15 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 0/10 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 03 Non-responders
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram vs Paroxetine
Mundo 1997a 7/11 5/9 1.15 [0.55, 2.39]
Subtotal (95% CI) 11 9 1.15 [0.55, 2.39]
Total events: 7 (SSRI 1), 5 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
03 Fluvoxamine vs Citalopram
Mundo 1997a 4/10 7/11 0.63 [0.26, 1.52]
Subtotal (95% CI) 10 11 0.63 [0.26, 1.52]
Total events: 4 (SSRI 1), 7 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 4/10 5/9 0.72 [0.28, 1.88]
Subtotal (95% CI) 10 9 0.72 [0.28, 1.88]
Total events: 4 (SSRI 1), 5 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
0.1 0.2 0.5 1 2 5 10
Favours SSRI 1
Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 04 Non-remitters
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Sertraline
Bergeron 2002 57/73 50/77 1.20 [0.98, 1.47]
Subtotal (95% CI) 73 77 1.20 [0.98, 1.47]
Total events: 57 (SSRI 1), 50 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.08)
0.5 0.7 1 1.5 2
Favours SSRI 1
Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 05 Y-BOCS
Study or sub-category
N
SSRI 1 Mean (SD)
N
SSRI 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
02 Fluoxetine vs Sertraline at 12 weeks
Bergeron 2002 72 -6.10(5.40) 76 -8.40(6.20) 0.39 [0.07, 0.72]
Subtotal (95% CI) 72 76 0.39 [0.07, 0.72]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.02)
03 Fluvoxamine vs Citalopram
Mundo 1997a 10 16.20(8.90) 11 19.80(10.10) -0.36 [-1.23, 0.50]
Subtotal (95% CI) 10 11 -0.36 [-1.23, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 10 16.20(8.90) 9 21.60(7.60) -0.62 [-1.55, 0.31]
Subtotal (95% CI) 10 9 -0.62 [-1.55, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
05 Paroxetine vs Citalopram
Mundo 1997a 9 21.60(7.60) 11 19.80(10.10) 0.19 [-0.69, 1.07]
Subtotal (95% CI) 9 11 0.19 [-0.69, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
-10 -5 0 5 10
Favours SSRI 1
Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 06 NIMH-OC
Study or sub-category
N
SSRI 1 Mean (SD)
N
SSRI 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Sertraline
Bergeron 2002 72 5.70(2.60) 76 5.50(2.80) 0.07 [-0.25, 0.40]
Subtotal (95% CI) 72 76 0.07 [-0.25, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
02 Fluvoxamine vs Citalopram
Mundo 1997a 10 6.23(1.81) 11 8.58(1.88) -1.22 [-2.17, -0.27]
Subtotal (95% CI) 10 11 -1.22 [-2.17, -0.27]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
03 Fluvoxamine vs Paroxetine
Mundo 1997a 10 6.23(1.81) 9 7.77(2.02) -0.77 [-1.71, 0.17]
Subtotal (95% CI) 10 9 -0.77 [-1.71, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
04 Paroxetine vs Citalopram
Mundo 1997a 9 7.77(2.02) 11 8.58(1.88) -0.40 [-1.29, 0.49]
Subtotal (95% CI) 9 11 -0.40 [-1.29, 0.49]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 07 Hamilton Rating Scale for Depression
Study or sub-category
N
SSRI 1 Mean (SD)
N
SSRI 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Sertraline
Bergeron 2002 72 7.10(5.40) 76 6.20(4.60) 0.18 [-0.14, 0.50]
Subtotal (95% CI) 72 76 0.18 [-0.14, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
-1 -0.5 0 0.5 1
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 01 Adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine vs Clomipramine
Freeman 1994 30/34 24/30 1.10 [0.89, 1.37]
Koran 1996a 35/37 39/41 0.99 [0.90, 1.10]
Mundo 2001 81/115 84/112 0.94 [0.80, 1.10]
Subtotal (95% CI) 186 183 0.98 [0.89, 1.09]
Total events: 146 (SSRI), 147 (Clomipramine)
Test for heterogeneity: Chi² = 1.47, df = 2 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
02 Paroxetine vs Clomipramine
Burnham 1993 77/82 80/82 0.96 [0.90, 1.03]
Zohar 1996a 163/201 85/99 0.94 [0.85, 1.05]
Subtotal (95% CI) 283 181 0.95 [0.89, 1.02]
Total events: 240 (SSRI), 165 (Clomipramine)
Test for heterogeneity: Chi² = 0.13, df = 1 (P = 0.72), I² = 0%
Test for overall effect: Z = 1.45 (P = 0.15)
03 Sertraline vs Clomipramine
Askin 1999 7/18 13/18 0.54 [0.28, 1.03]
Bisserbe 1997 56/86 57/82 0.94 [0.76, 1.16]
Subtotal (95% CI) 104 100 0.86 [0.71, 1.06]
Total events: 63 (SSRI), 70 (Clomipramine)
Test for heterogeneity: Chi² = 2.62, df = 1 (P = 0.11), I² = 61.8%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 573 464 0.95 [0.89, 1.00]
Total events: 449 (SSRI), 382 (Clomipramine)
Test for heterogeneity: Chi² = 5.93, df = 6 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.80 (P = 0.07)
0.5 0.7 1 1.5 2
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 02 Attempted suicide
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline vs Clomipramine
Bisserbe 1997 1/86 3/82 0.32 [0.03, 2.99]
Subtotal (95% CI) 86 82 0.32 [0.03, 2.99]
Total events: 1 (SSRI), 3 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.01 0.1 1 10 100
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 03 Leaving study early
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 5/30 4/25 1.04 [0.31, 3.47]
Subtotal (95% CI) 5/30 4/25 1.04 [0.31, 3.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
02 Fluvoxamine vs Clomipramine
Freeman 1994 6/34 11/32 0.51 [0.22, 1.23]
Koran 1996a 8/37 15/42 0.61 [0.29, 1.26]
Milanfranchi 1997 0/13 1/13 0.33 [0.01, 7.50]
Mundo 2001 19/115 26/112 0.71 [0.42, 1.21]
Smeraldi 1992 1/6 1/6 1.00 [0.08, 12.56]
Subtotal (95% CI) 34/205 54/205 0.64 [0.44, 0.93]
Test for heterogeneity: Chi² = 0.71, df = 4 (P = 0.95), I² = 0%
Test for overall effect: Z = 2.34 (P = 0.02)
03 Paroxetine vs Clomipramine
Burnham 1993 28/82 28/82 1.00 [0.65, 1.53]
Zohar 1996a 49/201 34/99 0.71 [0.49, 1.02]
Subtotal (95% CI) 77/283 62/181 0.82 [0.62, 1.08]
Test for heterogeneity: Chi² = 1.44, df = 1 (P = 0.23), I² = 30.4%
Test for overall effect: Z = 1.41 (P = 0.16)
04 Sertraline vs Clomipramine
Askin 1999 2/20 4/22 0.55 [0.11, 2.69]
Bisserbe 1997 23/86 35/82 0.63 [0.41, 0.96]
Subtotal (95% CI) 25/106 39/104 0.62 [0.41, 0.94]
Test for heterogeneity: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%
Test for overall effect: Z = 2.25 (P = 0.02)
Total (95% CI) 141/624 159/515 0.72 [0.59, 0.88]
Test for heterogeneity: Chi² = 4.26, df = 9 (P = 0.89), I² = 0%
Test for overall effect: Z = 3.29 (P = 0.001)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine

Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 04 Leaving study early due to adverse events




Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 05 Non-responders
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 22/30 11/25 1.67 [1.02, 2.73]
Subtotal (95% CI) 30 25 1.67 [1.02, 2.73]
Total events: 22 (SSRI), 11 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Fluvoxamine vs Clomipramine
Koran 1996a 18/37 21/42 0.97 [0.62, 1.52]
Milanfranchi 1997 2/13 3/13 0.67 [0.13, 3.35]
Mundo 2001 46/115 44/112 1.02 [0.74, 1.40]
Subtotal (95% CI) 165 167 0.99 [0.76, 1.28]
Total events: 66 (SSRI), 68 (Clomipramine)
Test for heterogeneity: Chi² = 0.27, df = 2 (P = 0.88), I² = 0%
Test for overall effect: Z = 0.08 (P = 0.93)
03 Paroxetine vs Clomipramine
Burnham 1993 47/82 42/82 1.12 [0.84, 1.48]
Zohar 1996a 92/201 47/99 0.96 [0.75, 1.25]
Subtotal (95% CI) 283 181 1.03 [0.85, 1.24]
Total events: 139 (SSRI), 89 (Clomipramine)
Test for heterogeneity: Chi² = 0.59, df = 1 (P = 0.44), I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)
04 Sertraline vs Clomipramine
Bisserbe 1997 24/86 29/82 0.79 [0.50, 1.24]
Subtotal (95% CI) 86 82 0.79 [0.50, 1.24]
Total events: 24 (SSRI), 29 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 564 455 1.02 [0.89, 1.17]
Total events: 251 (SSRI), 197 (Clomipramine)
Test for heterogeneity: Chi² = 6.01, df = 6 (P = 0.42), I² = 0.1%
Test for overall effect: Z = 0.24 (P = 0.81)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 06 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -7.50(9.29) 24 -8.90(7.13) 0.16 [-0.37, 0.70]
Subtotal (95% CI) 30 24 0.16 [-0.37, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
02 Fluvoxamine vs Clomipramine
Koran 1996a 34 17.80(7.70) 39 17.00(8.55) 0.10 [-0.36, 0.56]
Milanfranchi 1997 13 18.40(9.20) 12 16.50(11.00) 0.18 [-0.60, 0.97]
Mundo 2001 67 14.70(10.10) 61 12.50(8.00) 0.24 [-0.11, 0.59]
Smeraldi 1992 5 18.20(2.50) 5 15.20(12.40) 0.30 [-0.95, 1.55]
Subtotal (95% CI) 119 117 0.19 [-0.06, 0.45]
Test for heterogeneity: Chi² = 0.26, df = 3 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.46 (P = 0.14)
03 Paroxetine vs Clomipramine
Burnham 1993 79 -5.61(7.47) 78 -7.73(7.42) 0.28 [-0.03, 0.60]
Zohar 1996a 198 -8.00(8.00) 94 -8.00(8.20) 0.00 [-0.25, 0.25]
Subtotal (95% CI) 277 172 0.11 [-0.09, 0.30]
Test for heterogeneity: Chi² = 1.94, df = 1 (P = 0.16), I² = 48.4%
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 426 313 0.14 [-0.01, 0.29]
Test for heterogeneity: Chi² = 2.47, df = 6 (P = 0.87), I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Clomipramine

Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 07 NIMH-OC



Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 08 Comprehensive Psychopathological Rating Scale: obsessive-compulsive



Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 09 Hamilton Rating Scale for Depression




Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 10 Montgomery-Asberg Depression Rating Scale
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -10.10(8.20) 24 -13.80(9.09) 0.42 [-0.12, 0.97]
Subtotal (95% CI) 30 24 0.42 [-0.12, 0.97]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
02 Fluvoxamine vs Clomipramine
Smeraldi 1992 5 11.80(6.80) 5 9.60(10.30) 0.23 [-1.02, 1.47]
Subtotal (95% CI) 5 5 0.23 [-1.02, 1.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
03 Paroxetine vs Clomipramine
Zohar 1996a 198 -3.40(7.90) 94 -2.40(7.30) -0.13 [-0.38, 0.12]
Subtotal (95% CI) 198 94 -0.13 [-0.38, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 233 123 -0.03 [-0.25, 0.19]
Test for heterogeneity: Chi² = 3.47, df = 2 (P = 0.18), I² = 42.4%
Test for overall effect: Z = 0.24 (P = 0.81)
-4 -2 0 2 4
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 11 Depression (HRSD; MADRS)
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine vs Clomipramine
Koran 1996a 34 6.10(3.30) 39 5.80(4.70) 0.07 [-0.39, 0.53]
Mundo 2001 112 7.70(6.00) 105 7.00(4.50) 0.13 [-0.14, 0.40]
Smeraldi 1992 5 11.80(6.80) 5 9.60(10.30) 0.23 [-1.02, 1.47]
Subtotal (95% CI) 151 149 0.12 [-0.11, 0.35]
Test for heterogeneity: Chi² = 0.08, df = 2 (P = 0.96), I² = 0%
Test for overall effect: Z = 1.04 (P = 0.30)
02 Paroxetine vs Clomipramine
Zohar 1996a 198 -3.40(7.90) 94 -2.40(7.30) -0.13 [-0.38, 0.12]
Subtotal (95% CI) 198 94 -0.13 [-0.38, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 349 243 0.01 [-0.16, 0.17]
Test for heterogeneity: Chi² = 2.21, df = 3 (P = 0.53), I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)
-4 -2 0 2 4
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 12 Clinical Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine vs Clomipramine
Mundo 2001 112 7.00(4.60) 105 6.70(4.30) 0.07 [-0.20, 0.33]
Subtotal (95% CI) 112 105 0.07 [-0.20, 0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
-1 -0.5 0 0.5 1
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 13 Covi Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -2.40(3.10) 24 -2.40(3.09) 0.00 [-0.54, 0.54]
Subtotal (95% CI) 30 24 0.00 [-0.54, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 14 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale)



Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 15 Clinical Global Impressions: global improvement



Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 16 Clinical Global Impressions: severity of illness




Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 17 Symptom Checklist-90
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine vs Clomipramine
Zohar 1996a 169 -29.00(47.10) 74 -31.90(39.90) 0.06 [-0.21, 0.34]
Subtotal (95% CI) 169 74 0.06 [-0.21, 0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 18 Subanalysis: Non-responders in patients with comorbid depression
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 22/30 11/25 1.67 [1.02, 2.73]
Subtotal (95% CI) 30 25 1.67 [1.02, 2.73]
Total events: 22 (SSRI), 11 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Fluvoxamine vs Clomipramine
Mundo 2001 46/115 44/112 1.02 [0.74, 1.40]
Subtotal (95% CI) 115 112 1.02 [0.74, 1.40]
Total events: 46 (SSRI), 44 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 145 137 1.16 [0.88, 1.51]
Total events: 68 (SSRI), 55 (Clomipramine)
Test for heterogeneity: Chi² = 2.72, df = 1 (P = 0.10), I² = 63.3%
Test for overall effect: Z = 1.06 (P = 0.29)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 19 Subanalysis: Y-BOCS in patients with comorbid depression
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -7.50(9.29) 24 -8.90(7.13) 0.16 [-0.37, 0.70]
Subtotal (95% CI) 30 24 0.16 [-0.37, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
02 Fluvoxamine vs Clomipramine
Mundo 2001 67 14.70(10.10) 61 12.50(8.00) 0.24 [-0.11, 0.59]
Smeraldi 1992 5 18.20(2.50) 5 15.20(12.40) 0.30 [-0.95, 1.55]
Subtotal (95% CI) 72 66 0.24 [-0.09, 0.58]
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.92), I² = 0%
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 102 90 0.22 [-0.06, 0.51]
Test for heterogeneity: Chi² = 0.07, df = 2 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.52 (P = 0.13)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 20 Subanalysis: Hamilton Rating Scale for Depression in patients with comorbid depression
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -7.50(5.93) 24 -9.40(7.71) 0.28 [-0.26, 0.82]
Subtotal (95% CI) 30 24 0.28 [-0.26, 0.82]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
02 Fluvoxamine vs Clomipramine
Mundo 2001 112 7.70(6.00) 105 7.00(4.50) 0.13 [-0.14, 0.40]
Subtotal (95% CI) 112 105 0.13 [-0.14, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 142 129 0.16 [-0.08, 0.40]
Test for heterogeneity: Chi² = 0.22, df = 1 (P = 0.64), I² = 0%
Test for overall effect: Z = 1.31 (P = 0.19)
-1
-0.5
0
0.5
1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 01 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Phenelzine
Jenike 1997 19 16.20(6.30) 17 16.30(7.00) -0.01 [-0.67, 0.64]
Subtotal (95% CI) 19 17 -0.01 [-0.67, 0.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
02 Fluvoxamine vs Desipramine
Goodman 1990a 21 19.50(9.00) 19 25.80(6.00) -0.80 [-1.45, -0.15]
Subtotal (95% CI) 21 19 -0.80 [-1.45, -0.15]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.02)
03 Clomipramine vs Buspirone
Pato 1991 9 17.67(4.97) 9 16.78(6.46) 0.15 [-0.78, 1.07]
Subtotal (95% CI) 9 9 0.15 [-0.78, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
04 Sertraline vs Desipramine
Hoehn-Saric 2000 79 -8.40(8.00) 85 -6.00(8.30) -0.29 [-0.60, 0.02]
Subtotal (95% CI) 79 85 -0.29 [-0.60, 0.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.06)
Total (95% CI) 128 130 -0.30 [-0.54, -0.05]
Test for heterogeneity: Chi² = 3.91, df = 3 (P = 0.27), I² = 23.3%
Test for overall effect: Z = 2.35 (P = 0.02)
-4
-2
0
2
4
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 02 NIMH-OC
Study or sub-category
N
SSRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Phenelzine
Jenike 1997 19 7.00(1.10) 17 6.80(1.40) 0.16 [-0.50, 0.81]
Subtotal (95% CI) 19 17 0.16 [-0.50, 0.81]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
02 Sertraline vs Desipramine
Hoehn-Saric 2000 79 -2.70(2.67) 85 -1.70(2.77) -0.37 [-0.67, -0.06]
Subtotal (95% CI) 79 85 -0.37 [-0.67, -0.06]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.02)
03 Clomipramine vs Buspirone
Pato 1991 9 21.22(5.49) 9 19.22(5.97) 0.33 [-0.60, 1.26]
Subtotal (95% CI) 9 9 0.33 [-0.60, 1.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 107 111 -0.22 [-0.49, 0.05]
Test for heterogeneity: Chi² = 3.47, df = 2 (P = 0.18), I² = 42.3%
Test for overall effect: Z = 1.62 (P = 0.11)
-1
-0.5
0
0.5
1
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 03 Adverse events
Study or sub-category
SSRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline vs Desipramine
Hoehn-Saric 2000 79/80 84/86 1.01 [0.97, 1.05]
Subtotal (95% CI) 80 86 1.01 [0.97, 1.05]
Total events: 79 (SSRI), 84 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 80 86 1.01 [0.97, 1.05]
Total events: 79 (SSRI), 84 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
0.5
0.7
1
1.5
2
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 04 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline vs Desipramine
Hoehn-Saric 2000 8/80 22/86 0.39 [0.18, 0.83]
Subtotal (95% CI) 80 86 0.39 [0.18, 0.83]
Total events: 8 (SSRI), 22 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.01)
02 Clomipramine vs Imipramine
Volavka 1985 2/11 2/12 1.09 [0.18, 6.48]
Subtotal (95% CI) 11 12 1.09 [0.18, 6.48]
Total events: 2 (SSRI), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
03 Fluvoxamine vs Desipramine
Goodman 1990a 0/21 2/19 0.18 [0.01, 3.56]
Subtotal (95% CI) 21 19 0.18 [0.01, 3.56]
Total events: 0 (SSRI), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
04 Clomipramine vs Buspirone
Pato 1991 1/10 0/10 3.00 [0.14, 65.90]
Subtotal (95% CI) 10 10 3.00 [0.14, 65.90]
Total events: 1 (SSRI), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
05 Clomipramine vs Phenelzine
Vallejo 1992 1/16 0/14 2.65 [0.12, 60.21]
Subtotal (95% CI) 16 14 2.65 [0.12, 60.21]
Total events: 1 (SSRI), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 138 141 0.51 [0.28, 0.95]
Total events: 12 (SSRI), 26 (Other drug)
Test for heterogeneity: Chi² = 3.98, df = 4 (P = 0.41), I² = 0%
Test for overall effect: Z = 2.14 (P = 0.03)
0.001
0.01
0.1
1
10
100
1000
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 05 Non-responders (OCD)
Study or sub-category
SSRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
02 Sertraline vs Desipramine
Hoehn-Saric 2000 42/80 40/86 1.13 [0.83, 1.54]
Subtotal (95% CI) 80 86 1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 80 86 1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.5
0.7
1
1.5
2
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 01 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Beasley 1992 3/23 2/6 0.39 [0.08, 1.84]
Montgomery 1993 16/61 2/12 1.57 [0.41, 5.97]
Romano 2001 16/36 23/35 0.68 [0.44, 1.05]
Subtotal (95% CI) 120 53 0.75 [0.50, 1.12]
Total events: 35 (SSRI), 27 (Placebo)
Test for heterogeneity: Chi² = 2.07, df = 2 (P = 0.36), I² = 3.3%
Test for overall effect: Z = 1.40 (P = 0.16)
02 Paroxetine
Hollander 2003d 19/53 37/52 0.50 [0.34, 0.75]
Subtotal (95% CI) 53 52 0.50 [0.34, 0.75]
Total events: 19 (SSRI), 37 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.0008)
Total (95% CI) 173 105 0.61 [0.46, 0.81]
Total events: 54 (SSRI), 64 (Placebo)
Test for heterogeneity: Chi² = 3.36, df = 3 (P = 0.34), I² = 10.7%
Test for overall effect: Z = 3.39 (P = 0.0007)
0.01
0.1
1
10
100
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Montgomery 1993 2/61 0/12 1.05 [0.05, 20.58]
Romano 2001 2/36 1/35 1.94 [0.18, 20.49]
Subtotal (95% CI) 97 47 1.54 [0.25, 9.58]
Total events: 4 (SSRI), 1 (Placebo)
Test for heterogeneity: Chi² = 0.10, df = 1 (P = 0.75), I² = 0%
Test for overall effect: Z = 0.46 (P = 0.64)
02 Paroxetine
Hollander 2003d 3/53 20/52 0.15 [0.05, 0.47]
Subtotal (95% CI) 53 52 0.15 [0.05, 0.47]
Total events: 3 (SSRI), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.001)
Total (95% CI) 150 99 0.26 [0.11, 0.63]
Total events: 7 (SSRI), 21 (Placebo)
Test for heterogeneity: Chi² = 4.58, df = 2 (P = 0.10), I² = 56.3%
Test for overall effect: Z = 3.00 (P = 0.003)
0.01
0.1
1
10
100
Favours SSRI
Favours placebo

Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 03 Non-responders



Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 04 Y-BOCS



Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 05 Hamilton Rating Scale for Depression



Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 06 SF-36: social functioning



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 01 Death



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 02 Leaving study early



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 03 Leaving study early due to adverse effects



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 04 Relapse



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 05 Y-BOCS



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 06 NIMH-OC




Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 07 QoL Enjoyment and Satisfaction
Study or sub-category
SSRI N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Sertraline
Koran 2002 106 -77.30(16.10) 109 -67.50(20.30) -0.53 [-0.80, -0.26]
Subtotal (95% CI) 106 109 -0.53 [-0.80, -0.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.0001)
-1 -0.5 0 0.5 1
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 01 Leaving study early
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 40mg Fluoxetine v 20mg Fluoxetine
Beasley 1992 6/21 3/23 2.19 [0.63, 7.67]
Montgomery 1993 6/20 5/18 1.08 [0.40, 2.94]
Subtotal (95% CI) 41 41 1.47 [0.68, 3.19]
Total events: 12 (Dose 1), 8 (Dose 2)
Test for heterogeneity: Chi² = 0.75, df = 1 (P = 0.39), I² = 0%
Test for overall effect: Z = 0.98 (P = 0.33)
02 60mg Fluoxetine v 20mg Fluoxetine
Beasley 1992 3/26 3/23 0.88 [0.20, 3.96]
Montgomery 1993 5/23 5/18 0.78 [0.27, 2.29]
Subtotal (95% CI) 49 41 0.82 [0.34, 1.97]
Total events: 8 (Dose 1), 8 (Dose 2)
Test for heterogeneity: Chi² = 0.02, df = 1 (P = 0.90), I² = 0%
Test for overall effect: Z = 0.45 (P = 0.66)
03 60mg Fluoxetine v 40mg Fluoxetine
Beasley 1992 3/26 6/21 0.40 [0.11, 1.43]
Montgomery 1993 5/23 6/20 0.72 [0.26, 2.02]
Subtotal (95% CI) 49 41 0.56 [0.26, 1.24]
Total events: 8 (Dose 1), 12 (Dose 2)
Test for heterogeneity: Chi² = 0.50, df = 1 (P = 0.48), I² = 0%
Test for overall effect: Z = 1.43 (P = 0.15)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 40mg Fluoxetine v 20mg Fluoxetine
Montgomery 1993 1/20 0/18 2.71 [0.12, 62.70]
Subtotal (95% CI) 20 18 2.71 [0.12, 62.70]
Total events: 1 (Dose 1), 0 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
02 60mg Fluoxetine v 20mg Fluoxetine
Montgomery 1993 1/23 0/18 2.38 [0.10, 55.06]
Subtotal (95% CI) 23 18 2.38 [0.10, 55.06]
Total events: 1 (Dose 1), 0 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
03 60mg Fluoxetine v 40mg Fluoxetine
Montgomery 1993 1/23 1/20 0.87 [0.06, 13.02]
Subtotal (95% CI) 23 20 0.87 [0.06, 13.02]
Total events: 1 (Dose 1), 1 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.01 0.1 1 10 100
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 03 Non-responders
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine 40mg v Fluoxetine 20mg
Beasley 1992 12/21 14/23 0.94 [0.57, 1.54]
Subtotal (95% CI) 21 23 0.94 [0.57, 1.54]
Total events: 12 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
02 Fluoxetine 60mg v Fluoxetine 20mg
Beasley 1992 11/26 14/23 0.70 [0.40, 1.21]
Subtotal (95% CI) 26 23 0.70 [0.40, 1.21]
Total events: 11 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
03 Fluoxetine 60mg v Fluoxetine 40mg
Beasley 1992 11/26 12/21 0.74 [0.41, 1.32]
Subtotal (95% CI) 26 21 0.74 [0.41, 1.32]
Total events: 11 (Dose 1), 12 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
0.2 0.5 1 2 5
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 04 Y-BOCS
Study or sub-category
N
Dose 1 Mean (SD)
N
Dose 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine 40mg v Fluoxetine 20mg
Beasley 1992 21 9.40(6.00) 23 9.80(7.30) -0.06 [-0.65, 0.53]
Subtotal (95% CI) 21 23 -0.06 [-0.65, 0.53]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
02 Fluoxetine 60mg v Fluoxetine 20mg
Beasley 1992 26 7.00(5.40) 23 9.80(7.30) -0.43 [-1.00, 0.13]
Subtotal (95% CI) 26 23 -0.43 [-1.00, 0.13]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
03 Fluoxetine 60mg v Fluoxetine 40mg
Beasley 1992 26 7.00(5.40) 21 9.40(6.00) -0.42 [-1.00, 0.17]
Subtotal (95% CI) 26 21 -0.42 [-1.00, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
-4 -2 0 2 4
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 09 SSRIs v Clomipramine (continuation phase)
Outcome: 01 Leaving study early
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine 60mg vs Clomipramine 200mg (non-responders)
Lopez-Ibor 1996 6/14 3/8 1.14 [0.39, 3.36]
Subtotal (95% CI) 14 8 1.14 [0.39, 3.36]
Total events: 6 (SSRI), 3 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
02 Fluoxetine 20mg vs Clomipramine 100mg (responders)
Lopez-Ibor 1996 3/11 6/13 0.59 [0.19, 1.83]
Subtotal (95% CI) 11 13 0.59 [0.19, 1.83]
Total events: 3 (SSRI), 6 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 09 SSRIs vs Clomipramine (continuation phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine 60mg vs Clomipramine 200mg (non-responders)
Lopez-Ibor 1996 2/14 0/8 3.00 [0.16, 55.72]
Subtotal (95% CI) 14 8 3.00 [0.16, 55.72]
Total events: 2 (SSRI), 0 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
02 Fluoxetine 20mg vs Clomipramine 100mg (responders)
Lopez-Ibor 1996 1/11 1/13 1.18 [0.08, 16.78]
Subtotal (95% CI) 11 13 1.18 [0.08, 16.78]
Total events: 1 (SSRI), 1 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
0.01 0.1 1 10 100
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 09 SSRIs vs Clomipramine (continuation phase)
Outcome: 03 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine 60mg vs Clomipramine 200mg (non-responders)
Lopez-Ibor 1996 11 8.80(5.79) 13 13.70(11.79) -0.50 [-1.31, 0.32]
Subtotal (95% CI) 11 13 -0.50 [-1.31, 0.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
02 Fluoxetine 20mg vs Clomipramine 100mg (responders)
Lopez-Ibor 1996 14 24.00(7.54) 8 15.00(9.32) 1.05 [0.12, 1.99]
Subtotal (95% CI) 14 8 1.05 [0.12, 1.99]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.03)
Total (95% CI) 25 21 0.18 [-0.44, 0.79]
Test for heterogeneity: Chi² = 5.99, df = 1 (P = 0.01), I² = 83.3%
Test for overall effect: Z = 0.56 (P = 0.57)
-4 -2 0 2 4
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 10 Sertraline standard dose vs high dose (non-responders)
Outcome: 01 Leaving study early
Study or sub-category
Standard dose 200mg n/N
High dose 250-400mg n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 2002a 6/36 9/30 0.56 [0.22, 1.38]
Total (95% CI) 36 30 0.56 [0.22, 1.38]
Total events: 6 (Standard dose 200mg), 9 (High dose 250-400mg)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
0.1 0.2 0.5 1 2 5 10
Favours standard Favours high


Review: OCD adults: SSRIs
Comparison: 10 Sertraline standard dose vs high dose (non-responders)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
Standard dose 200mg n/N
High dose 250-400mg n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 2002a 2/36 0/30 4.19 [0.21, 84.03]
Total (95% CI) 36 30 4.19 [0.21, 84.03]
Total events: 2 (Standard dose 200mg), 0 (High dose 250-400mg)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
0.01 0.1 1 10 100
Favours standard Favours high


Review: OCD adults: SSRIs
Comparison: 10 Sertraline standard dose vs high dose (non-responders)
Outcome: 03 Non-responders
Study or sub-category
Standard dose 200mg n/N
High dose 250-400mg n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 2002a 24/36 18/30 1.11 [0.77, 1.61]
Total (95% CI) 36 30 1.11 [0.77, 1.61]
Total events: 24 (Standard dose 200mg), 18 (High dose 250-400mg)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
0.1 0.2 0.5 1 2 5 10
Favours standard Favours high


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 01 Leaving the study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 19/51 7/12 0.64 [0.35, 1.16]
Subtotal (95% CI) 51 12 0.64 [0.35, 1.16]
Total events: 19 (SSRI), 7 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 02 Leaving the study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 2/12 0.94 [0.23, 3.88]
Subtotal (95% CI) 51 12 0.94 [0.23, 3.88]
Total events: 8 (SSRI), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 03 Adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 42/51 8/12 1.24 [0.81, 1.88]
Subtotal (95% CI) 51 12 1.24 [0.81, 1.88]
Total events: 42 (SSRI), 8 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 04 Severe adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 18/51 3/12 1.41 [0.49, 4.03]
Subtotal (95% CI) 51 12 1.41 [0.49, 4.03]
Total events: 18 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 05 Non-responders (Y-BOCS 25% reduction)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 3/12 0.63 [0.20, 2.02]
Subtotal (95% CI) 51 12 0.63 [0.20, 2.02]
Total events: 8 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 06 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine
Ansseau 1995 51 -14.70(7.20) 12 -11.00(6.90) -0.51 [-1.15, 0.12]
Subtotal (95% CI) 51 12 -0.51 [-1.15, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 07 NIMH-OCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine
Ansseau 1995 51 -5.20(2.60) 12 -3.60(2.60) -0.61 [-1.25, 0.03]
Subtotal (95% CI) 51 12 -0.61 [-1.25, 0.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.06)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 01 Leaving the study early
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 19/51 8/20 0.93 [0.49, 1.77]
Subtotal (95% CI) 51 20 0.93 [0.49, 1.77]
Total events: 19 (SSRI), 8 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 02 Leaving the study early due to adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 6/20 0.52 [0.21, 1.32]
Subtotal (95% CI) 51 20 0.52 [0.21, 1.32]
Total events: 8 (SSRI), 6 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 03 Adverse events



Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 04 Severe adverse events



Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 05 Responders (Y-BOCS 25% reduction)



Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 06 Y-BOCS



Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 07 NIMH-OCS



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 01 Leaving the study early



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 02 Leaving the study early due to adverse events



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 03 Full relapse (Y-BOCS and CGI Severity increase)



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 04 Partial relapse (Y-BOCS or CGI Severity increase)



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 05 Adverse events



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 06 Severe adverse events







Clomipramine (OCD, adults)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 02 Leaving study early



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 03 Leaving study early due to adverse events



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 04 Non-responders (Y-BOCS)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 05 Non-responders (CGI)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 06 Non-responders (all)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 07 Non-remitters



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 08 Y-BOCS



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 09 OCD Scale (CPRS)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 10 6-item OCD Scale - amelioration



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 11 OCD (OCD-CPRS; 6-item OCD Scale-amelioration)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 12 Y-BOCS/CPRS



Removing heterogeneity from Clomipramine v Placebo (Y-BOCS/CPRS): Burnham1993 and Zohar1996a removed because they reported change scores

Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 12 Y-BOCS/CPRS



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 13 NIMH-OC



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 14 Leyton Obsessional Inventory: symptom



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 15 Leyton Obsessional Inventory: trait



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 16 Leyton Obsessional Inventory: resistance



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 17 Leyton Obsessional Inventory: interference



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 18 Self-Rating Obsessive-Compulsive Personality Inventory



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 19 Montgomery-Asberg Depression Rating Scale



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 20 Clinical Global Impressions: severity of illness



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 21 Symptom Checklist-90




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 01 Adverse events
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Freeman 1994 24/30 30/34 0.91 [0.73, 1.13]
Koran 1996a 39/41 35/37 1.01 [0.91, 1.12]
Mundo 2001 84/112 81/115 1.06 [0.91, 1.25]
Subtotal (95% CI) 183 186 1.02 [0.92, 1.13]
Total events: 147 (Clomipramine), 146 (SSRI)
Test for heterogeneity: Chi² = 1.47, df = 2 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
02 Clomipramine vs Paroxetine
Burnham 1993 80/82 77/82 1.04 [0.97, 1.11]
Zohar 1996a 85/99 163/201 1.06 [0.95, 1.17]
Subtotal (95% CI) 181 283 1.05 [0.98, 1.12]
Total events: 165 (Clomipramine), 240 (SSRI)
Test for heterogeneity: Chi² = 0.13, df = 1 (P = 0.72), I² = 0%
Test for overall effect: Z = 1.45 (P = 0.15)
03 Clomipramine vs Sertraline
Askin 1999 13/18 7/18 1.86 [0.97, 3.54]
Bisserbe 1997 57/82 56/86 1.07 [0.86, 1.32]
Subtotal (95% CI) 100 104 1.16 [0.95, 1.42]
Total events: 70 (Clomipramine), 63 (SSRI)
Test for heterogeneity: Chi² = 2.62, df = 1 (P = 0.11), I² = 61.8%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 464 573 1.06 [1.00, 1.12]
Total events: 382 (Clomipramine), 449 (SSRI)
Test for heterogeneity: Chi² = 5.93, df = 6 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.80 (P = 0.07)
0.2
0.5
1
2
5
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 02 Attempted suicide
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Sertraline
Bisserbe 1997 3/82 1/86 3.15 [0.33, 29.64]
Subtotal (95% CI) 82 86 3.15 [0.33, 29.64]
Total events: 3 (Clomipramine), 1 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.01
0.1
1
10
100
Favours Clomipramine
Favours SSRI

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 03 Leaving study early




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 04 Leaving study early due to adverse events
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 1/25 1/30 1.20 [0.08, 18.23]
Subtotal (95% CI) 25 30 1.20 [0.08, 18.23]
Total events: 1 (Clomipramine), 1 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
02 Clomipramine vs Fluvoxamine
Freeman 1994 4/30 5/34 0.91 [0.27, 3.07]
Koran 1996a 7/42 5/37 1.23 [0.43, 3.56]
Milanfranchi 1997 0/13 0/13 Not estimable
Mundo 2001 18/112 9/115 2.05 [0.96, 4.38]
Smeraldi 1992 0/6 1/6 0.33 [0.02, 6.86]
Subtotal (95% CI) 203 205 1.45 [0.85, 2.46]
Total events: 29 (Clomipramine), 20 (SSRI)
Test for heterogeneity: Chi² = 2.38, df = 3 (P = 0.50), I² = 0%
Test for overall effect: Z = 1.38 (P = 0.17)
03 Clomipramine vs Paroxetine
Burnham 1993 17/82 15/82 1.13 [0.61, 2.11]
Zohar 1996a 17/99 18/201 1.92 [1.03, 3.56]
Subtotal (95% CI) 181 283 1.48 [0.96, 2.29]
Total events: 34 (Clomipramine), 33 (SSRI)
Test for heterogeneity: Chi² = 1.38, df = 1 (P = 0.24), I² = 27.5%
Test for overall effect: Z = 1.77 (P = 0.08)
04 Clomipramine vs Sertraline
Bisserbe 1997 21/82 9/86 2.45 [1.19, 5.03]
Subtotal (95% CI) 82 86 2.45 [1.19, 5.03]
Total events: 21 (Clomipramine), 9 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
Total (95% CI) 491 604 1.61 [1.19, 2.18]
Total events: 85 (Clomipramine), 63 (SSRI)
Test for heterogeneity: Chi² = 5.41, df = 7 (P = 0.61), I² = 0%
Test for overall effect: Z = 3.11 (P = 0.002)
0.01 0.1 1 10 100
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 05 Non-responders (25% Y-BOCS)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Koran 1996a 21/42 18/37 1.03 [0.66, 1.61]
Subtotal (95% CI) 42 37 1.03 [0.66, 1.61]
Total events: 21 (Clomipramine), 18 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
02 Clomipramine vs Paroxetine
Zohar 1996a 47/99 92/201 1.04 [0.80, 1.34]
Subtotal (95% CI) 99 201 1.04 [0.80, 1.34]
Total events: 47 (Clomipramine), 92 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 141 238 1.03 [0.83, 1.29]
Total events: 68 (Clomipramine), 110 (SSRI)
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 0.97), I² = 0%
Test for overall effect: Z = 0.30 (P = 0.76)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 06 Non-responders (35% Y-BOCS)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Mundo 2001 44/112 46/115 0.98 [0.71, 1.35]
Subtotal (95% CI) 112 115 0.98 [0.71, 1.35]
Total events: 44 (Clomipramine), 46 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 07 Non-responders (CGI; 25% Y-BOCS)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 11/25 22/30 0.60 [0.37, 0.98]
Subtotal (95% CI) 25 30 0.60 [0.37, 0.98]
Total events: 11 (Clomipramine), 22 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Clomipramine vs Paroxetine
Burnham 1993 42/82 47/82 0.89 [0.67, 1.18]
Subtotal (95% CI) 82 82 0.89 [0.67, 1.18]
Total events: 42 (Clomipramine), 47 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI) 107 112 0.81 [0.63, 1.03]
Total events: 53 (Clomipramine), 69 (SSRI)
Test for heterogeneity: Chi² = 1.90, df = 1 (P = 0.17), I² = 47.3%
Test for overall effect: Z = 1.73 (P = 0.08)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 09 Non-responders (CGI-I)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Milanfranchi 1997 3/13 2/13 1.50 [0.30, 7.55]
Subtotal (95% CI) 13 13 1.50 [0.30, 7.55]
Total events: 3 (Clomipramine), 2 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
02 Clomipramine vs Sertraline
Bisserbe 1997 29/82 24/86 1.27 [0.81, 1.98]
Subtotal (95% CI) 82 86 1.27 [0.81, 1.98]
Total events: 29 (Clomipramine), 24 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 95 99 1.29 [0.83, 1.98]
Total events: 32 (Clomipramine), 26 (SSRI)
Test for heterogeneity: Chi² = 0.04, df = 1 (P = 0.84), I² = 0%
Test for overall effect: Z = 1.14 (P = 0.25)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 10 Non-responders (all)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 11/25 22/30 0.60 [0.37, 0.98]
Subtotal (95% CI) 25 30 0.60 [0.37, 0.98]
Total events: 11 (Clomipramine), 22 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Clomipramine vs Fluvoxamine
Koran 1996a 21/42 18/37 1.03 [0.66, 1.61]
Milanfranchi 1997 3/13 2/13 1.50 [0.30, 7.55]
Mundo 2001 44/112 46/115 0.98 [0.71, 1.35]
Subtotal (95% CI) 167 165 1.01 [0.78, 1.31]
Total events: 68 (Clomipramine), 66 (SSRI)
Test for heterogeneity: Chi² = 0.27, df = 2 (P = 0.88), I² = 0%
Test for overall effect: Z = 0.08 (P = 0.93)
03 Clomipramine vs Paroxetine
Burnham 1993 42/82 47/82 0.89 [0.67, 1.18]
Zohar 1996a 47/99 92/201 1.04 [0.80, 1.34]
Subtotal (95% CI) 181 283 0.97 [0.81, 1.18]
Total events: 89 (Clomipramine), 139 (SSRI)
Test for heterogeneity: Chi² = 0.59, df = 1 (P = 0.44), I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)
04 Clomipramine vs Sertraline
Bisserbe 1997 29/82 24/86 1.27 [0.81, 1.98]
Subtotal (95% CI) 82 86 1.27 [0.81, 1.98]
Total events: 29 (Clomipramine), 24 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 455 564 0.98 [0.85, 1.13]
Total events: 197 (Clomipramine), 251 (SSRI)
Test for heterogeneity: Chi² = 6.01, df = 6 (P = 0.42), I² = 0.1%
Test for overall effect: Z = 0.24 (P = 0.81)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 11 Y-BOCS
Study or sub-category
Clomipramine N Mean (SD)
SSRI N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 24 -8.90(7.13) 30 -7.50(9.29) -0.16 [-0.70, 0.37]
Subtotal (95% CI) 24 30 -0.16 [-0.70, 0.37]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
02 Clomipramine vs Fluvoxamine
Koran 1996a 39 17.00(8.55) 34 17.80(7.70) -0.10 [-0.56, 0.36]
Milanfranchi 1997 12 16.50(11.00) 13 18.40(9.20) -0.18 [-0.97, 0.60]
Mundo 2001 61 12.50(8.00) 67 14.70(10.10) -0.24 [-0.59, 0.11]
Smeraldi 1992 5 15.20(12.40) 5 18.20(2.50) -0.30 [-1.55, 0.95]
Subtotal (95% CI) 117 119 -0.19 [-0.45, 0.06]
Test for heterogeneity: Chi² = 0.26, df = 3 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.46 (P = 0.14)
03 Clomipramine vs Paroxetine
Burnham 1993 78 -7.73(7.42) 79 -5.61(7.47) -0.28 [-0.60, 0.03]
Zohar 1996a 94 -8.00(8.20) 198 -8.00(8.00) 0.00 [-0.25, 0.25]
Subtotal (95% CI) 172 277 -0.11 [-0.30, 0.09]
Test for heterogeneity: Chi² = 1.94, df = 1 (P = 0.16), I² = 48.4%
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 313 426 -0.14 [-0.29, 0.01]
Test for heterogeneity: Chi² = 2.47, df = 6 (P = 0.87), I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
-1 -0.5 0 0.5 1
Favours Clomipramine
Favours SSRI

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 12 NIMH-OC



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 13 Comprehensive Psychopathological Rating Scale: obsessive-compulsive



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 14 Hamilton Rating Scale for Depression




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 15 Montgomery-Asberg Depression Rating Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 24 -13.80(9.09) 30 -10.10(8.20) -0.42 [-0.97, 0.12]
Subtotal (95% CI) 24 30 -0.42 [-0.97, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
02 Clomipramine vs Fluvoxamine
Smeraldi 1992 5 9.60(10.30) 5 11.80(6.80) -0.23 [-1.47, 1.02]
Subtotal (95% CI) 5 5 -0.23 [-1.47, 1.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
03 Clomipramine vs Paroxetine
Zohar 1996a 94 -2.40(7.30) 198 -3.40(7.90) 0.13 [-0.12, 0.38]
Subtotal (95% CI) 94 198 0.13 [-0.12, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 123 233 0.03 [-0.19, 0.25]
Test for heterogeneity: Chi² = 3.47, df = 2 (P = 0.18), I² = 42.4%
Test for overall effect: Z = 0.24 (P = 0.81)
-4 -2 0 2 4
Favours Clomipramine Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 16 Depression (HRSD; MADRS)
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Koran 1996a 39 5.80(4.70) 34 6.10(3.30) -0.07 [-0.53, 0.39]
Mundo 2001 105 7.00(4.50) 112 7.70(6.00) -0.13 [-0.40, 0.14]
Smeraldi 1992 5 9.60(10.30) 5 11.80(6.80) -0.23 [-1.47, 1.02]
Subtotal (95% CI) 149 151 -0.12 [-0.35, 0.11]
Test for heterogeneity: Chi² = 0.08, df = 2 (P = 0.96), I² = 0%
Test for overall effect: Z = 1.04 (P = 0.30)
02 Clomipramine vs Paroxetine
Zohar 1996a 94 -2.40(7.30) 198 -3.40(7.90) 0.13 [-0.12, 0.38]
Subtotal (95% CI) 94 198 0.13 [-0.12, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 243 349 -0.01 [-0.17, 0.16]
Test for heterogeneity: Chi² = 2.21, df = 3 (P = 0.53), I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)
-4 -2 0 2 4
Favours Clomipramine Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 17 Clinical Anxiety Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Mundo 2001 105 6.70(4.30) 112 7.00(4.60) -0.07 [-0.33, 0.20]
Subtotal (95% CI) 105 112 -0.07 [-0.33, 0.20]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
-1 -0.5 0 0.5 1
Favours Clomipramine Favours SSRI

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 18 Covi Anxiety Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 24 -2.40(3.09) 30 -2.40(3.10) 0.00 [-0.54, 0.54]
Subtotal (95% CI) 24 30 0.00 [-0.54, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-10 -5 0 5 10
Favours Clomipramine Favours SSRI

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 19 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale)



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 20 Clinical Global Impressions: global improvement



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 21 Clinical Global Impressions: severity of illness




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 22 Symptom Checklist-90
Study or sub-category
Clomipramine N Mean (SD)
SSRI N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Paroxetine
Zohar 1996a 74 -31.90(39.90) 169 -29.00(47.10) -0.06 [-0.34, 0.21]
Subtotal (95% CI) 74 169 -0.06 [-0.34, 0.21]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
-1 -0.5 0 0.5 1
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 01 Leaving study early
Study or sub-category
Clomipramine n/N
TCA n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 3/11 4/12 0.82 [0.23, 2.87]
Subtotal (95% CI) 11 12 0.82 [0.23, 2.87]
Total events: 3 (Clomipramine), 4 (TCA)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
02 Clomipramine vs Amitriptyline
Ananth 1981 1/10 2/10 0.50 [0.05, 4.67]
Subtotal (95% CI) 10 10 0.50 [0.05, 4.67]
Total events: 1 (Clomipramine), 2 (TCA)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 21 22 0.71 [0.24, 2.12]
Total events: 4 (Clomipramine), 6 (TCA)
Test for heterogeneity: Chi² = 0.14, df = 1 (P = 0.70), I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)
0.01 0.1 1 10 100
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category
Clomipramine n/N
TCA n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 2/11 2/12 1.09 [0.18, 6.48]
Subtotal (95% CI) 11 12 1.09 [0.18, 6.48]
Total events: 2 (Clomipramine), 2 (TCA)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 03 Leyton Obsessional Inventory: symptom
Study or sub-category
Clomipramine N Mean (SD)
TCA N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Nortriptyline
Thoren 1980a 8 -4.40(9.60) 8 -3.00(3.10) -0.19 [-1.17, 0.80]
Subtotal (95% CI) 8 8 -0.19 [-1.17, 0.80]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
-4 -2 0 2 4
Favours Clomipramine
Favours TCA

Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 04 Leyton Obsessional Inventory: trait



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 05 Leyton Obsessional Inventory: resistance



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 06 Leyton Obsessional Inventory: interference



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 07 CPRS: obsessive-compulsive



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 08 Self-Rating Obsessive Compulsive Personality Inventory



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 09 Self-Rating Obsessional Neurotic Scale



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 10 Hamilton Rating Scale for Depression

Study or sub-category	N	Clomipramine Mean (SD)	N	TCA Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Clomipramine vs Imipramine						
Volavka 1985	8	2.01(2.20)	8	6.20(4.90)		-1.04 [-2.11, 0.02]
Subtotal (95% CI)	8		8			-1.04 [-2.11, 0.02]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.92 (P = 0.05)						



Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 11 Global Evaluation of Efficacy

Study or sub-category	N	Clomipramine Mean (SD)	N	TCA Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Clomipramine vs Imipramine						
Volavka 1985	8	1.75(0.89)	8	2.88(1.13)		-1.05 [-2.12, 0.02]
Subtotal (95% CI)	8		8			-1.05 [-2.12, 0.02]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.93 (P = 0.05)						



Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 01 Adverse effects

Study or sub-category	Clomipramine n/N	Other drug n/N	RR (fixed) 95% CI	RR (fixed) 95% CI
01 Clomipramine vs Venlafaxine				
Albert 2002	43/47	16/26		1.49 [1.08, 2.04]
Subtotal (95% CI)	47	26		1.49 [1.08, 2.04]
Total events: 43 (Clomipramine), 16 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 2.46 (P = 0.01)				



Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 02 Leaving study early

Study or sub-category	Clomipramine n/N	Other drug n/N	RR (fixed) 95% CI	RR (fixed) 95% CI
01 Clomipramine vs Buspirone				
Pato 1991	1/10	1/10		1.00 [0.07, 13.87]
Subtotal (95% CI)	10	10		1.00 [0.07, 13.87]
Total events: 1 (Clomipramine), 1 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.00 (P = 1.00)				
02 Clomipramine vs Phenelzine				
Vallejo 1992	2/16	2/14		0.88 [0.14, 5.42]
Subtotal (95% CI)	16	14		0.88 [0.14, 5.42]
Total events: 2 (Clomipramine), 2 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.14 (P = 0.89)				
03 Clomipramine vs Venlafaxine				
Albert 2002	7/47	1/26		3.87 [0.50, 29.77]
Subtotal (95% CI)	47	26		3.87 [0.50, 29.77]
Total events: 7 (Clomipramine), 1 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 1.30 (P = 0.19)				




Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 03 Leaving study early due to adverse effects
Study or sub-category
Clomipramine n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 1/10 0/10 3.00 [0.14, 65.90]
Subtotal (95% CI) 10 10 3.00 [0.14, 65.90]
Total events: 1 (Clomipramine), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
02 Clomipramine vs Phenelzine
Vallejo 1992 1/16 0/14 2.65 [0.12, 60.21]
Subtotal (95% CI) 16 14 2.65 [0.12, 60.21]
Total events: 1 (Clomipramine), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
03 Clomipramine vs Venlafaxine
Albert 2002 5/47 0/26 6.19 [0.36, 107.66]
Subtotal (95% CI) 47 26 6.19 [0.36, 107.66]
Total events: 5 (Clomipramine), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
0.001 0.01 0.1 1 10 100 1000
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 04 Non-responders
Study or sub-category
Clomipramine n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Venlafaxine
Albert 2002 27/47 17/26 0.88 [0.61, 1.28]
Subtotal (95% CI) 47 26 0.88 [0.61, 1.28]
Total events: 27 (Clomipramine), 17 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.5 0.7 1 1.5 2
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 05 Y-BOCS
Study or sub-category
N
Clomipramine Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 9 17.67(4.97) 9 16.78(6.46) 0.15 [-0.78, 1.07]
Subtotal (95% CI) 9 9 0.15 [-0.78, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
02 Clomipramine vs Venlafaxine
Albert 2002 47 17.30(6.15) 26 18.36(7.11) -0.16 [-0.64, 0.32]
Subtotal (95% CI) 47 26 -0.16 [-0.64, 0.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 06 NIMH-OC
Study or sub-category
N
Clomipramine Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 9 5.22(1.20) 9 5.11(1.27) 0.08 [-0.84, 1.01]
Subtotal (95% CI) 9 9 0.08 [-0.84, 1.01]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 07 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
Clomipramine N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Phenelzine
Vallejo 1992 14 12.10(4.70) 12 10.10(6.90) 0.33 [-0.44, 1.11]
Subtotal (95% CI) 14 12 0.33 [-0.44, 1.11]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 08 Hamilton Rating Scale for Depression
Study or sub-category
Clomipramine N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 9 9.33(4.58) 9 9.89(6.75) -0.09 [-1.02, 0.83]
Subtotal (95% CI) 9 9 -0.09 [-1.02, 0.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
02 Clomipramine vs Phenelzine
Vallejo 1992 14 11.50(6.90) 12 7.00(5.70) 0.68 [-0.11, 1.48]
Subtotal (95% CI) 14 12 0.68 [-0.11, 1.48]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.09)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 09 Hamilton Rating Scale for Anxiety
Study or sub-category
Clomipramine N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Phenelzine
Vallejo 1992 14 14.10(8.70) 12 7.00(6.60) 0.88 [0.07, 1.69]
Subtotal (95% CI) 14 12 0.88 [0.07, 1.69]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.03)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 01 Leaving study early
Study or sub-category
IV Clomipramine n/N
IV Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Fallon 1998 1/29 2/25 0.43 [0.04, 4.48]
Total (95% CI) 29 25 0.43 [0.04, 4.48]
Total events: 1 (IV Clomipramine), 2 (IV Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
0.01 0.1 1 10 100
Favours Clomipramine
Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 02 Non-responders
Study or sub-category
IV Clomipramine n/N
IV Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Fallon 1998 23/29 25/25 0.79 [0.66, 0.96]
Total (95% CI) 29 25 0.79 [0.66, 0.96]
Total events: 23 (IV Clomipramine), 25 (IV Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
0.5 0.7 1 1.5 2
Favours Clomipramine
Favours Placebo

Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 03 Y-BOCS



Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 04 NIMH-OC



Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 05 Clinical Global Impressions: severity



Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 06 Hamilton Rating Scale for Depression



Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 01 Adverse effects



Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 02 Leaving study early



Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 03 Non-responders



Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 04 Y-BOCS



Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 01 Adverse effects



Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 02 Leaving study early due to adverse effects



Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 03 NIMH-OC



Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 04 Physician's Global Evaluation



Review: OCD adults: Clomipramine
Comparison: 08 Clomipramine vs SSRIs: continuation phase
Outcome: 01 Leaving study early



Review: OCD adults: Clomipramine
Comparison: 08 Clomipramine vs SSRIs: continuation phase
Outcome: 02 Leaving study early due to adverse effects




Review: OCD adults: Clomipramine
Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation
Outcome: 01 Leaving study early
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Same dose (150mg) vs half dose (75mg)
Ravizza 1996a 2/14 0/15 5.33 [0.28, 102.26]
Subtotal (95% CI) 14 15 5.33 [0.28, 102.26]
Total events: 2 (Dose 1), 0 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
02 Same dose (150mg) vs none
Ravizza 1996a 2/14 1/14 2.00 [0.20, 19.62]
Subtotal (95% CI) 14 14 2.00 [0.20, 19.62]
Total events: 2 (Dose 1), 1 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
03 Half dose (75mg) vs none
Ravizza 1996a 0/15 1/14 0.31 [0.01, 7.09]
Subtotal (95% CI) 15 14 0.31 [0.01, 7.09]
Total events: 0 (Dose 1), 1 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.001 0.01 0.1 1 10 100 1000
Favours Dose 1
Favours Dose 2


Review: OCD adults: Clomipramine
Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation
Outcome: 02 Relapse (CGI; 25% Y-BOCS)
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Same dose (150mg) vs half dose (75mg)
Ravizza 1996a 5/14 4/15 1.34 [0.45, 4.00]
Subtotal (95% CI) 14 15 1.34 [0.45, 4.00]
Total events: 5 (Dose 1), 4 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
02 Same dose (150mg) vs none
Ravizza 1996a 5/14 11/14 0.45 [0.21, 0.97]
Subtotal (95% CI) 14 14 0.45 [0.21, 0.97]
Total events: 5 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.04)
03 Half dose (75mg) vs none
Ravizza 1996a 4/15 11/14 0.34 [0.14, 0.82]
Subtotal (95% CI) 15 14 0.34 [0.14, 0.82]
Total events: 4 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.02)
04 Continuation v discontinuation
Ravizza 1996a 9/29 11/14 0.39 [0.22, 0.73]
Subtotal (95% CI) 29 14 0.39 [0.22, 0.73]
Total events: 9 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.003)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1
Favours Dose 2

TCAs (OCD)

Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 01 Leyton Obsessional Inventory: symptom

Study or sub-category	N	TCA Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline						
Thoren 1980a	8	-3.00(3.10)	8	-1.00(2.30)		-0.69 [-1.71, 0.33]
Subtotal (95% CI)	8		8			-0.69 [-1.71, 0.33]

Test for heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)



Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 02 Leyton Obsessional Inventory: trait

Study or sub-category	N	TCA Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline						
Thoren 1980a	8	-1.50(1.10)	8	-0.50(3.00)		-0.42 [-1.41, 0.58]
Subtotal (95% CI)	8		8			-0.42 [-1.41, 0.58]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)



Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 03 Leyton Obsessional Inventory: resistance

Study or sub-category	N	TCA Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline						
Thoren 1980a	8	-4.60(15.90)	8	-4.30(18.60)		-0.02 [-1.00, 0.96]
Subtotal (95% CI)	8		8			-0.02 [-1.00, 0.96]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)



Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 04 Leyton Obsessional Inventory: interference

Study or sub-category	N	TCA Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline						
Thoren 1980a	8	-19.00(15.90)	8	-8.40(15.90)		-0.63 [-1.64, 0.38]
Subtotal (95% CI)	8		8			-0.63 [-1.64, 0.38]

Test for heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)



Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 05 OCD Scale (CPRS)

Study or sub-category	N	TCA Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline						
Thoren 1980a	8	7.31(2.89)	8	8.75(3.18)		-0.45 [-1.44, 0.55]
Subtotal (95% CI)	8		8			-0.45 [-1.44, 0.55]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)




Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 01 Adverse effects
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 85/86 80/80 0.99 [0.97, 1.01]
Subtotal (95% CI) 86 80 0.99 [0.97, 1.01]
Total events: 85 (TCA), 80 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.5 0.7 1 1.5 2
Favours TCA Favours other drug
Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 02 Leaving study early
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Amitriptyline vs Clomipramine
Ananth 1981 2/10 1/10 2.00 [0.21, 18.69]
Subtotal (95% CI) 10 10 2.00 [0.21, 18.69]
Total events: 2 (TCA), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
02 Desipramine vs Fluvoxamine
Goodman 1990a 6/19 2/21 3.32 [0.76, 14.49]
Subtotal (95% CI) 19 21 3.32 [0.76, 14.49]
Total events: 6 (TCA), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
03 Desipramine vs Sertraline
Hoehn-Saric 2000 33/86 14/80 2.19 [1.27, 3.79]
Subtotal (95% CI) 86 80 2.19 [1.27, 3.79]
Total events: 33 (TCA), 14 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.005)
04 Imipramine vs Clomipramine
Volavka 1985 4/12 3/11 1.22 [0.35, 4.28]
Subtotal (95% CI) 12 11 1.22 [0.35, 4.28]
Total events: 4 (TCA), 3 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
0.01 0.1 1 10 100
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 03 Leaving study early due to adverse effects
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Fluvoxamine
Goodman 1990a 2/19 0/21 5.50 [0.28, 107.78]
Subtotal (95% CI) 19 21 5.50 [0.28, 107.78]
Total events: 2 (TCA), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
02 Desipramine vs Sertraline
Hoehn-Saric 2000 23/86 9/80 2.38 [1.17, 4.83]
Subtotal (95% CI) 86 80 2.38 [1.17, 4.83]
Total events: 23 (TCA), 9 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.02)
03 Imipramine vs Clomipramine
Volavka 1985 2/12 2/11 0.92 [0.15, 5.44]
Subtotal (95% CI) 12 11 0.92 [0.15, 5.44]
Total events: 2 (TCA), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.001 0.01 0.1 1 10 100 1000
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 04 Non-responders (OCD)
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 40/86 42/80 0.89 [0.65, 1.21]
Subtotal (95% CI) 86 80 0.89 [0.65, 1.21]
Total events: 40 (TCA), 42 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 05 Non-responders (MDD)
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 43/86 29/80 1.38 [0.96, 1.98]
Subtotal (95% CI) 86 80 1.38 [0.96, 1.98]
Total events: 43 (TCA), 29 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.08)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 06 Non-remitters (HRSD>17)
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 56/86 41/80 1.27 [0.98, 1.65]
Subtotal (95% CI) 86 80 1.27 [0.98, 1.65]
Total events: 56 (TCA), 41 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.08)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 07 Y-BOCS
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Desipramine vs Fluvoxamine
Goodman 1990a 19 25.80(6.00) 21 19.50(9.00) 0.80 [0.15, 1.45]
Subtotal (95% CI) 19 21 0.80 [0.15, 1.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.02)
02 Desipramine vs Sertraline
Hoehn-Saric 2000 85 -6.00(8.30) 79 -8.40(8.00) 0.29 [-0.02, 0.60]
Subtotal (95% CI) 85 79 0.29 [-0.02, 0.60]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.06)
Total (95% CI) 104 100 0.39 [0.11, 0.66]
Test for heterogeneity: Chi² = 1.92, df = 1 (P = 0.17), I² = 47.8%
Test for overall effect: Z = 2.72 (P = 0.006)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 08 NIMH-OC
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 85 -1.70(2.77) 79 -2.70(2.67) 0.37 [0.06, 0.67]
Subtotal (95% CI) 85 79 0.37 [0.06, 0.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.02)
-1 -0.5 0 0.5 1
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 09 Leyton Obsessional Inventory: symptom
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -3.00(3.10) 8 -4.40(9.60) 0.19 [-0.80, 1.17]
Subtotal (95% CI) 8 8 0.19 [-0.80, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 10 Leyton Obsessional Inventory: trait
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -1.50(1.10) 8 -1.90(2.30) 0.21 [-0.77, 1.19]
Subtotal (95% CI) 8 8 0.21 [-0.77, 1.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 11 Leyton Obsessional Inventory: resistance
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -4.60(15.90) 8 -13.00(19.60) 0.45 [-0.55, 1.44]
Subtotal (95% CI) 8 8 0.45 [-0.55, 1.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours TCA Favours other drug

Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 12 Leyton Obsessional Inventory: interference

Study or sub-category	N	TCA Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine						
Thoren 1980a	8	-19.00(15.90)	8	-12.30(24.00)		-0.31 [-1.30, 0.68]
Subtotal (95% CI)	8		8			-0.31 [-1.30, 0.68]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.62 (P = 0.54)						



Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 13 CPRS: obsessive-compulsive

Study or sub-category	N	TCA Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine						
Thoren 1980a	8	7.31(2.89)	8	6.38(2.75)		0.31 [-0.68, 1.30]
Subtotal (95% CI)	8		8			0.31 [-0.68, 1.30]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.62 (P = 0.54)						



Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 14 Self-Rating Obsessive Compulsive Personality Inventory

Study or sub-category	N	TCA Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Imipramine vs Clomipramine						
Volavka 1985	8	68.70(12.90)	8	47.90(14.40)		1.44 [0.30, 2.57]
Subtotal (95% CI)	8		8			1.44 [0.30, 2.57]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.48 (P = 0.01)						



Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 15 Self-Rating Obsessional Neurotic Scale

Study or sub-category	N	TCA Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Imipramine vs Clomipramine						
Volavka 1985	8	63.60(20.50)	8	41.90(13.90)		1.17 [0.09, 2.26]
Subtotal (95% CI)	8		8			1.17 [0.09, 2.26]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.11 (P = 0.03)						



Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 16 Hamilton Rating Scale for Depression

Study or sub-category	N	TCA Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Desipramine vs Fluvoxamine						
Goodman 1990a	19	22.30(13.00)	21	17.70(15.00)		0.32 [-0.30, 0.94]
Subtotal (95% CI)	19		21			0.32 [-0.30, 0.94]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.00 (P = 0.32)						
02 Desipramine vs Sertraline						
Hoehn-Saric 2000	85	-11.50(10.14)	79	-14.80(9.78)		0.33 [0.02, 0.64]
Subtotal (95% CI)	85		79			0.33 [0.02, 0.64]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.09 (P = 0.04)						
03 Imipramine vs Clomipramine						
Volavka 1985	8	6.20(4.90)	8	2.01(2.20)		1.04 [-0.02, 2.11]
Subtotal (95% CI)	8		8			1.04 [-0.02, 2.11]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.92 (P = 0.05)						




Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 17 Global Evaluation of Efficacy
Study or sub-category
TCA N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Imipramine vs Clomipramine
Volavka 1985 8 2.88(1.13) 8 1.75(0.89) 1.05 [-0.02, 2.12]
Subtotal (95% CI) 8 8 1.05 [-0.02, 2.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.05)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 01 Leaving the study early (only during the 2-month substitution period)
Study or sub-category
Desipramine n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Leonard 1991a 1/10 0/11 3.27 [0.15, 72.23]
Total (95% CI) 10 11 3.27 [0.15, 72.23]
Total events: 1 (Desipramine), 0 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
0.01 0.1 1 10 100
Favours Desipramine
Favours Clomipramine


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 02 Relapse (Physician's Relapse Scale)
Study or sub-category
Desipramine n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Leonard 1991a 8/9 2/11 4.89 [1.37, 17.49]
Total (95% CI) 9 11 4.89 [1.37, 17.49]
Total events: 8 (Desipramine), 2 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
0.01 0.1 1 10 100
Favours Desipramine
Favours Clomipramine


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive
Study or sub-category
Desipramine N Mean (SD)
Clomipramine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Leonard 1991a 9 6.30(3.30) 11 5.20(4.00) 0.28 [-0.60, 1.17]
Total (95% CI) 9 11 0.28 [-0.60, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
-4 -2 0 2 4
Favours Desipramine
Favours Clomipramine


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 04 NIMH-OC
Study or sub-category
Desipramine N Mean (SD)
Clomipramine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Leonard 1991a 9 5.80(0.40) 11 5.00(2.30) 0.44 [-0.45, 1.34]
Total (95% CI) 9 11 0.44 [-0.45, 1.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
-4 -2 0 2 4
Favours Desipramine
Favours Clomipramine

SNRIs (OCD)

Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 01 Adverse effects



Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 02 Leaving study early



Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 03 Leaving study early due to adverse effects



Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 04 Non-responders




Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 05 Y-BOCS
Study or sub-category
N
SNRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 73 -7.20(7.50) 72 -7.80(5.40) 0.09 [-0.23, 0.42]
Subtotal (95% CI) 73 72 0.09 [-0.23, 0.42]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
02 Venlafaxine vs Clomipramine
Albert 2002 26 18.36(7.11) 47 17.30(6.15) 0.16 [-0.32, 0.64]
Subtotal (95% CI) 26 47 0.16 [-0.32, 0.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
-1 -0.5 0 0.5 1
Favours SNRI
Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 06 Hamilton Rating Scale for Depression
Study or sub-category
N
SNRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 73 -2.80(5.60) 72 -3.50(4.60) 0.14 [-0.19, 0.46]
Subtotal (95% CI) 73 72 0.14 [-0.19, 0.46]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
-0.5 -0.25 0 0.25 0.5
Favours SNRI
Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category
N
SNRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 73 -4.90(5.00) 72 -4.70(7.00) -0.03 [-0.36, 0.29]
Subtotal (95% CI) 73 72 -0.03 [-0.36, 0.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
-0.5 -0.25 0 0.25 0.5
Favours SNRI
Favours other drug

MAOIs (OCD)


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 01 Leaving study early
Study or sub-category
MAOI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 3/20 3/21 1.05 [0.24, 4.61]
Subtotal (95% CI) 20 21 1.05 [0.24, 4.61]
Total events: 3 (MAOI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
0.2 0.5 1 2 5
Favours MAOI
Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 02 Y-BOCS
Study or sub-category
N
MAOI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 16.30(7.00) 18 18.70(6.10) -0.36 [-1.03, 0.31]
Subtotal (95% CI) 17 18 -0.36 [-1.03, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
-4 -2 0 2 4
Favours MAOI
Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 03 NIMH-OC
Study or sub-category | N | MAOI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 6.80(1.40) 18 7.20(1.30) -0.29 [-0.96, 0.38]
Subtotal (95% CI) 17 18 -0.29 [-0.96, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
-1 -0.5 0 0.5 1
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 04 OCD Scale (CPRS)
Study or sub-category | N | MAOI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 6.50(3.80) 18 5.80(3.30) 0.19 [-0.47, 0.86]
Subtotal (95% CI) 17 18 0.19 [-0.47, 0.86]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
-1 -0.5 0 0.5 1
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 05 Clinical Global Impression
Study or sub-category | N | MAOI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 3.20(1.00) 18 3.20(1.00) 0.00 [-0.66, 0.66]
Subtotal (95% CI) 17 18 0.00 [-0.66, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 01 Leaving study early
Study or sub-category | MAOI n/N | Other drug n/N | RR (fixed) 95% CI | RR (fixed) 95% CI
01 Phenelzine vs Clomipramine
Vallejo 1992 2/14 2/16 1.14 [0.18, 7.08]
Subtotal (95% CI) 14 16 1.14 [0.18, 7.08]
Total events: 2 (MAOI), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
02 Phenelzine vs Fluoxetine
Jenike 1997 3/20 4/23 0.86 [0.22, 3.40]
Subtotal (95% CI) 20 23 0.86 [0.22, 3.40]
Total events: 3 (MAOI), 4 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
0.1 0.2 0.5 1 2 5 10
Favours MAOI Favours other drug


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category | MAOI n/N | Other drug n/N | RR (fixed) 95% CI | RR (fixed) 95% CI
01 Phenelzine vs Clomipramine
Vallejo 1992 0/14 1/16 0.38 [0.02, 8.59]
Subtotal (95% CI) 14 16 0.38 [0.02, 8.59]
Total events: 0 (MAOI), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
0.01 0.1 1 10 100
Favours MAOI Favours other drug

Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 03 Y-BOCS

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetine						
Jenike 1997	17	16.30(7.00)	19	16.20(6.30)		0.01 [-0.64, 0.67]
Subtotal (95% CI)	17		19			0.01 [-0.64, 0.67]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.04 (P = 0.96)						



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 04 NIMH-OC

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetine						
Jenike 1997	17	6.80(1.40)	19	7.00(1.10)		-0.16 [-0.81, 0.50]
Subtotal (95% CI)	17		19			-0.16 [-0.81, 0.50]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.47 (P = 0.64)						



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 05 Maudsley Obsessive-Compulsive Inventory

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Phenelzine vs Clomipramine						
Vallejo 1992	12	10.10(6.90)	14	12.10(4.70)		-0.33 [-1.11, 0.44]
Subtotal (95% CI)	12		14			-0.33 [-1.11, 0.44]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.84 (P = 0.40)						



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 06 OCD Scale (CPRS)

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetine						
Jenike 1997	17	6.50(3.80)	19	6.70(2.60)		-0.06 [-0.72, 0.59]
Subtotal (95% CI)	17		19			-0.06 [-0.72, 0.59]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.18 (P = 0.86)						



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 07 Hamilton Rating Scale for Depression

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Phenelzine vs Clomipramine						
Vallejo 1992	12	7.00(5.70)	14	11.50(6.90)		-0.68 [-1.48, 0.11]
Subtotal (95% CI)	12		14			-0.68 [-1.48, 0.11]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.68 (P = 0.09)						







Anxiolytics (OCD)








Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 04 Y-BOCS
Study or sub-category
Anxiolytic N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clonazepam
Hollander 2003c 16 -1.70(4.30) 9 -0.67(5.10) -0.22 [-1.04, 0.60]
Subtotal (95% CI) 16 9 -0.22 [-1.04, 0.60]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
-10 -5 0 5 10
Favours anxiolytic
Favours placebo


Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 05 NIMH-OC
Study or sub-category
Anxiolytic N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clonazepam
Hollander 2003c 16 0.13(2.40) 9 0.00(2.50) 0.05 [-0.77, 0.87]
Subtotal (95% CI) 16 9 0.05 [-0.77, 0.87]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
-4 -2 0 2 4
Favours anxiolytic
Favours placebo


Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 06 Hamilton Rating Scale for Depression
Study or sub-category
Anxiolytic N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clonazepam
Hollander 2003c 16 0.44(5.20) 9 1.10(8.10) -0.10 [-0.92, 0.72]
Subtotal (95% CI) 16 9 -0.10 [-0.92, 0.72]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
-10 -5 0 5 10
Favours anxiolytic
Favours placebo


Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category
Anxiolytic N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clonazepam
Hollander 2003c 16 -1.10(7.70) 9 0.33(9.80) -0.16 [-0.98, 0.66]
Subtotal (95% CI) 16 9 -0.16 [-0.98, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
-10 -5 0 5 10
Favours anxiolytic
Favours placebo


Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs other drugs
Outcome: 01 Leaving study early
Study or sub-category
Anxiolytic n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Buspirone vs Clomipramine
Pato 1991 1/10 1/10 1.00 [0.07, 13.87]
Subtotal (95% CI) 10 10 1.00 [0.07, 13.87]
Total events: 1 (Anxiolytic), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.01 0.1 1 10 100
Favours anxiolytic
Favours other drug









Other Pharmacological (OCD)



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 01 Adverse effects



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 02 Leaving study early



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 03 Hamilton Depression Scale



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 04 Self Rating Depression Scale



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 05 Hamilton Anxiety Scale







Augmentation (OCD)








Review: OCD: augmentation strategies
Comparison: 01 Buspirone vs placebo
Outcome: 04 Hamilton Anxiety Scale
Study or sub-category
FLV+Buspirone N Mean (SD)
FLV+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Buspirone v FLV+Placebo
McDougle 1993a 19 11.60(6.80) 14 8.60(4.90) 0.48 [-0.22, 1.18]
Subtotal (95% CI) 19 14 0.48 [-0.22, 1.18]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 01 Non-responders (Y-BOCS 35%)
Study or sub-category
Citalopram+CMI n/N
Citalopram n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Pallanti 1999 0/9 6/7 0.06 [0.00, 0.94]
Total (95% CI) 9 7 0.06 [0.00, 0.94]
Total events: 0 (Citalopram+CMI), 6 (Citalopram)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.04)
0.001 0.01 0.1 1 10 100 1000
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 02 Y-BOCS
Study or sub-category
Citalopram+CMI N Mean (SD)
Citalopram N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Pallanti 1999 9 15.90(3.80) 7 25.60(4.80) -2.15 [-3.46, -0.84]
Total (95% CI) 9 7 -2.15 [-3.46, -0.84]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.001)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 03 Hamilton Depression Rating Scale
Study or sub-category
Citalopram+CMI N Mean (SD)
Citalopram N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Pallanti 1999 9 5.60(2.60) 7 6.40(1.80) -0.33 [-1.33, 0.67]
Total (95% CI) 9 7 -0.33 [-1.33, 0.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 03 Desipramine vs placebo
Outcome: 01 Y-BOCS at 6 weeks
Study or sub-category
SSRI+Desipramine N Mean (SD)
SSRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SSRI+Desipramine v SSRI+Placebo
Barr 1997 10 18.52(2.94) 13 24.52(2.94) -1.97 [-3.00, -0.93]
Subtotal (95% CI) 10 13 -1.97 [-3.00, -0.93]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.0002)
-4 -2 0 2 4
Favours augmentation
Favours non-aug

Review: OCD: augmentation strategies
Comparison: 03 Desipramine vs placebo
Outcome: 02 Y-BOCS at 10 weeks



Review: OCD: augmentation strategies
Comparison: 04 Haloperidol vs placebo
Outcome: 01 Non-responders



Review: OCD: augmentation strategies
Comparison: 04 Haloperidol vs placebo
Outcome: 02 Y-BOCS



Review: OCD: augmentation strategies
Comparison: 05 Inositol vs placebo
Outcome: 01 Y-BOCS


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 01 Non-responders
Study or sub-category
FLV+Lithium n/N
FLV+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 9/11 9/9 0.82 [0.62, 1.08]
Subtotal (95% CI) 11 9 0.82 [0.62, 1.08]
Total events: 9 (FLV+Lithium), 9 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5/5 5/5 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (FLV+Lithium), 0 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 16 14 0.82 [0.62, 1.08]
Total events: 14 (FLV+Lithium), 14 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
0.5 0.7 1 1.5 2
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 02 Y-BOCS change score
Study or sub-category
N
FLV+Lithium Mean (SD)
N
FLV+Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 11 -4.00(5.23) 9 1.22(5.24) -0.96 [-1.90, -0.01]
Subtotal (95% CI) 11 9 -0.96 [-1.90, -0.01]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.05)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5 2.60(3.58) 5 -1.40(2.07) 1.24 [-0.19, 2.66]
Subtotal (95% CI) 5 5 1.24 [-0.19, 2.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
Total (95% CI) 16 14 -0.29 [-1.07, 0.50]
Test for heterogeneity: Chi² = 6.34, df = 1 (P = 0.01), I² = 84.2%
Test for overall effect: Z = 0.72 (P = 0.47)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 03 Hamilton Depression Scale change score
Study or sub-category
N
FLV+Lithium Mean (SD)
N
FLV+Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 11 -7.00(8.81) 9 0.00(9.06) -0.75 [-1.67, 0.17]
Subtotal (95% CI) 11 9 -0.75 [-1.67, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5 4.60(6.15) 5 -3.40(4.28) 1.36 [-0.09, 2.82]
Subtotal (95% CI) 5 5 1.36 [-0.09, 2.82]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.07)
Total (95% CI) 16 14 -0.15 [-0.93, 0.63]
Test for heterogeneity: Chi² = 5.79, df = 1 (P = 0.02), I² = 82.7%
Test for overall effect: Z = 0.38 (P = 0.70)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 04 Hamilton Anxiety Scale change score
Study or sub-category
FLV+Lithium N Mean (SD)
FLV+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 11 -0.73(4.67) 9 -1.11(3.26) 0.09 [-0.79, 0.97]
Subtotal (95% CI) 11 9 0.09 [-0.79, 0.97]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5 1.40(3.51) 5 -3.20(3.27) 1.22 [-0.19, 2.64]
Subtotal (95% CI) 5 5 1.22 [-0.19, 2.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.09)
Total (95% CI) 16 14 0.41 [-0.34, 1.15]
Test for heterogeneity: Chi² = 1.78, df = 1 (P = 0.18), I² = 43.8%
Test for overall effect: Z = 1.06 (P = 0.29)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 07 Nortriptyline vs placebo
Outcome: 01 Y-BOCS
Study or sub-category
CMI+Nortriptyline N Mean (SD)
CMI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CMI+Nortriptyline v CMI+Placebo
Noorbala 1998 15 8.33(5.56) 15 19.17(5.56) -1.90 [-2.78, -1.02]
Subtotal (95% CI) 15 15 -1.90 [-2.78, -1.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.22 (P < 0.0001)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 01 Leaving the study early
Study or sub-category
FLX+Olanzapine n/N
FLX+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 5/22 2/22 2.50 [0.54, 11.54]
Subtotal (95% CI) 22 22 2.50 [0.54, 11.54]
Total events: 5 (FLX+Olanzapine), 2 (FLX+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 02 Leaving the study early due to adverse effects
Study or sub-category
FLX+Olanzapine n/N
FLX+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 2/22 2/22 1.00 [0.15, 6.48]
Subtotal (95% CI) 22 22 1.00 [0.15, 6.48]
Total events: 2 (FLX+Olanzapine), 2 (FLX+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 03 Non-responders (Y-BOCS 25%)
Study or sub-category
FLX+Olanzapine n/N
FLX+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 13/22 13/22 1.00 [0.61, 1.64]
Subtotal (95% CI) 22 22 1.00 [0.61, 1.64]
Total events: 13 (FLX+Olanzapine), 13 (FLX+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.5 0.7 1 1.5 2
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 04 Y-BOCS change score
Study or sub-category
FLX+Olanzapine N Mean (SD)
FLX+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 22 -5.10(4.90) 22 -3.80(3.80) -0.29 [-0.89, 0.30]
Subtotal (95% CI) 22 22 -0.29 [-0.89, 0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
-1 -0.5 0 0.5 1
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 01 Leaving the study early
Study or sub-category
Paroxetine+Pindolol n/N
Paroxetine+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 PAR+Pindolol v PAR+Placebo
Dannon 2000 0/8 2/8 0.20 [0.01, 3.61]
Subtotal (95% CI) 8 8 0.20 [0.01, 3.61]
Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 02 Leaving the study early due to adverse effects
Study or sub-category
Paroxetine+Pindolol n/N
Paroxetine+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 PAR+Pindolol v PAR+Placebo
Dannon 2000 0/8 2/8 0.20 [0.01, 3.61]
Subtotal (95% CI) 8 8 0.20 [0.01, 3.61]
Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 03 Y-BOCS
Study or sub-category
Paroxetine+Pindolol N Mean (SD)
Paroxetine+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 PAR+Pindolol v PAR+Placebo
Dannon 2000 8 21.40(3.70) 6 28.80(2.40) -2.15 [-3.56, -0.73]
Subtotal (95% CI) 8 6 -2.15 [-3.56, -0.73]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.003)
-4 -2 0 2 4
Favours augmentation
Favours non-aug

Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 04 MADRS



Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 05 Hamilton Anxiety Scale



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 01 Adverse effects



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 02 Leaving the study early



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 03 Non-responders (Y-BOCS 30%)



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 04 Y-BOCS

Study or sub-category	N	SRI+Quetiapine Mean (SD)	N	SRI+Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo						
Atmaca 2002	14	13.40(3.20)	13	21.40(4.30)		-2.06 [-3.02, -1.10]
Subtotal (95% CI)	14		13			-2.06 [-3.02, -1.10]

Test for heterogeneity: not applicable
Test for overall effect: Z = 4.20 (P < 0.0001)



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 05 CGI: severity of illness

Study or sub-category	N	SRI+Quetiapine Mean (SD)	N	SRI+Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo						
Atmaca 2002	14	2.42(0.80)	13	3.76(1.40)		-1.15 [-1.98, -0.33]
Subtotal (95% CI)	14		13			-1.15 [-1.98, -0.33]

Test for heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.006)



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 01 Adverse effects

Study or sub-category	SRI+Risperidone n/N	SRI+Placebo n/N	RR (fixed) 95% CI	RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo				
Hollander 2003e	4/10	2/6		1.20 [0.31, 4.69]
McDougle 2000a	18/20	15/16		0.96 [0.79, 1.16]
Subtotal (95% CI)	30	22		0.99 [0.77, 1.28]

Total events: 22 (SRI+Risperidone), 17 (SRI+Placebo)
Test for heterogeneity: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 02 Leaving the study early

Study or sub-category	SRI+Risperidone n/N	SRI+Placebo n/N	RR (fixed) 95% CI	RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo				
Hollander 2003e	1/10	2/6		0.30 [0.03, 2.65]
McDougle 2000a	2/20	1/16		1.60 [0.16, 16.10]
Subtotal (95% CI)	30	22		0.70 [0.16, 3.01]

Total events: 3 (SRI+Risperidone), 3 (SRI+Placebo)
Test for heterogeneity: Chi² = 1.07, df = 1 (P = 0.30), I² = 6.9%
Test for overall effect: Z = 0.48 (P = 0.63)



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 03 Leaving the study early due to adverse effects

Study or sub-category	SRI+Risperidone n/N	SRI+Placebo n/N	RR (fixed) 95% CI	RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo				
McDougle 2000a	1/20	0/16		2.43 [0.11, 55.89]
Subtotal (95% CI)	20	16		2.43 [0.11, 55.89]

Total events: 1 (SRI+Risperidone), 0 (SRI+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 04 Non-responders



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 05 Y-BOCS change score



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 06 Hamilton Depression Scale



Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 07 Hamilton Anxiety Scale




Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 01 Adverse effects
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 9/14 4/13 2.09 [0.85, 5.16]
Subtotal (95% CI) 14 13 2.09 [0.85, 5.16]
Total events: 9 (Augmentation), 4 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
02 SRI+Risperidone v SRI+Placebo
Hollander 2003e 4/10 2/6 1.20 [0.31, 4.69]
McDougle 2000a 18/20 15/16 0.96 [0.79, 1.16]
Subtotal (95% CI) 30 22 0.99 [0.77, 1.28]
Total events: 22 (Augmentation), 17 (non-augmentation)
Test for heterogeneity: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)
Total (95% CI) 44 35 1.19 [0.89, 1.58]
Total events: 31 (Augmentation), 21 (non-augmentation)
Test for heterogeneity: Chi² = 6.13, df = 2 (P = 0.05), I² = 67.3%
Test for overall effect: Z = 1.17 (P = 0.24)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 02 Leaving the study early
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 5/22 2/22 2.50 [0.54, 11.54]
Subtotal (95% CI) 22 22 2.50 [0.54, 11.54]
Total events: 5 (Augmentation), 2 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
02 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 0/14 0/13 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Augmentation), 0 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 SRI+Risperidone v SRI+Placebo
Hollander 2003e 1/10 2/6 0.30 [0.03, 2.65]
McDougle 2000a 2/20 1/16 1.60 [0.16, 16.10]
Subtotal (95% CI) 30 22 0.70 [0.16, 3.01]
Total events: 3 (Augmentation), 3 (non-augmentation)
Test for heterogeneity: Chi² = 1.07, df = 1 (P = 0.30), I² = 6.9%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 66 57 1.34 [0.49, 3.67]
Total events: 8 (Augmentation), 5 (non-augmentation)
Test for heterogeneity: Chi² = 2.48, df = 2 (P = 0.29), I² = 19.3%
Test for overall effect: Z = 0.57 (P = 0.57)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 03 Leaving the study early due to adverse effects
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 2/22 2/22 1.00 [0.15, 6.48]
Subtotal (95% CI) 22 22 1.00 [0.15, 6.48]
Total events: 2 (Augmentation), 2 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
02 SRI+Risperidone v SRI+Placebo
McDougle 2000a 1/20 0/16 2.43 [0.11, 55.89]
Subtotal (95% CI) 20 16 2.43 [0.11, 55.89]
Total events: 1 (Augmentation), 0 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 42 38 1.31 [0.27, 6.35]
Total events: 3 (Augmentation), 2 (non-augmentation)
Test for heterogeneity: Chi² = 0.23, df = 1 (P = 0.63), I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 04 Non-responders
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLV+Haloperidol v FLV+Placebo
McDougle 1994a 10/17 17/17 0.59 [0.40, 0.88]
Subtotal (95% CI) 17 17 0.59 [0.40, 0.88]
Total events: 10 (Augmentation), 17 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.009)
02 FLX+Olanzapine v FLX+Placebo
Shapira 2004 13/22 13/22 1.00 [0.61, 1.64]
Subtotal (95% CI) 22 22 1.00 [0.61, 1.64]
Total events: 13 (Augmentation), 13 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
03 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 4/14 13/13 0.29 [0.12, 0.65]
Subtotal (95% CI) 14 13 0.29 [0.12, 0.65]
Total events: 4 (Augmentation), 13 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.003)
04 SRI+Risperidone v SRI+Placebo
Hollander 2003e 6/10 6/6 0.60 [0.36, 1.00]
McDougle 2000a 16/20 16/16 0.80 [0.64, 1.00]
Subtotal (95% CI) 30 22 0.74 [0.60, 0.91]
Total events: 22 (Augmentation), 22 (non-augmentation)
Test for heterogeneity: Chi² = 1.14, df = 1 (P = 0.29), I² = 12.3%
Test for overall effect: Z = 2.81 (P = 0.005)
Total (95% CI) 83 74 0.66 [0.54, 0.81]
Total events: 49 (Augmentation), 65 (non-augmentation)
Test for heterogeneity: Chi² = 9.98, df = 4 (P = 0.04), I² = 59.9%
Test for overall effect: Z = 4.05 (P < 0.0001)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 05 Y-BOCS
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 FLV+Haloperidol v FLV+Placebo
McDougle 1994a 17 18.53(2.71) 17 23.18(1.10) -2.20 [-3.07, -1.32]
Subtotal (95% CI) 17 17 -2.20 [-3.07, -1.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.94 (P < 0.00001)
02 FLX+Olanzapine v FLX+Placebo
Shapira 2004 22 -5.10(4.90) 22 -3.80(3.80) -0.29 [-0.89, 0.30]
Subtotal (95% CI) 22 22 -0.29 [-0.89, 0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
03 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 14 13.40(3.20) 13 21.40(4.30) -2.06 [-3.02, -1.10]
Subtotal (95% CI) 14 13 -2.06 [-3.02, -1.10]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.20 (P < 0.0001)
04 SRI+Risperidone v SRI+Placebo
Hollander 2003e 10 -6.10(8.18) 6 -1.33(3.14) -0.66 [-1.71, 0.38]
McDougle 2000a 20 -8.00(7.32) 16 -6.60(0.97) -0.25 [-0.91, 0.41]
Subtotal (95% CI) 30 22 -0.37 [-0.92, 0.19]
Test for heterogeneity: Chi² = 0.43, df = 1 (P = 0.51), I² = 0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 83 74 -0.84 [-1.19, -0.50]
Test for heterogeneity: Chi² = 21.94, df = 4 (P = 0.0002), I² = 81.8%
Test for overall effect: Z = 4.80 (P < 0.00001)
-4 -2 0 2 4
Favours augmentation Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 06 Hamilton Depression Scale
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 18 7.60(4.90) 15 15.20(8.70) -1.08 [-1.82, -0.34]
Subtotal (95% CI) 18 15 -1.08 [-1.82, -0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.004)
-4 -2 0 2 4
Favours augmentation Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 18 9.10(4.30) 15 15.40(6.90) -1.09 [-1.83, -0.35]
Subtotal (95% CI) 18 15 -1.09 [-1.83, -0.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.004)
-4 -2 0 2 4
Favours augmentation Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 08 CGI: severity of illness
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 14 2.42(0.80) 13 3.76(1.40) -1.15 [-1.98, -0.33]
Subtotal (95% CI) 14 13 -1.15 [-1.98, -0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.006)
-4 -2 0 2 4
Favours augmentation Favours non-aug

SSRIs (OCD, children)

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 01 Adverse events



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 02 Serious adverse events



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 03 Leaving the study early




Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 04 Leaving the study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 6/71 2/32 1.35 [0.29, 6.34]
Liebowitz 2002 0/21 0/22 Not estimable
Riddle 1992 1/7 0/6 2.63 [0.13, 54.64]
Subtotal (95% CI) 99 60 1.56 [0.40, 6.10]
Total events: 7 (SSRI), 2 (Placebo)
Test for heterogeneity: Chi² = 0.15, df = 1 (P = 0.70), I² = 0%
Test for overall effect: Z = 0.64 (P = 0.52)
02 Fluvoxamine
Riddle 2001 3/57 1/63 3.32 [0.35, 30.98]
Subtotal (95% CI) 57 63 3.32 [0.35, 30.98]
Total events: 3 (SSRI), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
03 Sertraline
March 1998 12/92 3/95 4.13 [1.20, 14.16]
POTS 2004 1/28 0/28 3.00 [0.13, 70.64]
Subtotal (95% CI) 120 123 3.97 [1.26, 12.48]
Total events: 13 (SSRI), 3 (Placebo)
Test for heterogeneity: Chi² = 0.03, df = 1 (P = 0.85), I² = 0%
Test for overall effect: Z = 2.36 (P = 0.02)
04 Paroxetine
Geller 2004 10/98 3/105 3.57 [1.01, 12.60]
Subtotal (95% CI) 98 105 3.57 [1.01, 12.60]
Total events: 10 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.05)
Total (95% CI) 374 351 3.05 [1.55, 6.00]
Total events: 33 (SSRI), 9 (Placebo)
Test for heterogeneity: Chi² = 1.37, df = 5 (P = 0.93), I² = 0%
Test for overall effect: Z = 3.24 (P = 0.001)
0.01 0.1 1 10 100
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 05 Non-responders (25% CY-BOCS)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine
Riddle 2001 33/57 46/63 0.79 [0.61, 1.04]
Subtotal (95% CI) 57 63 0.79 [0.61, 1.04]
Total events: 33 (SSRI), 46 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
02 Paroxetine
Geller 2004 39/100 65/107 0.64 [0.48, 0.86]
Subtotal (95% CI) 100 107 0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.003)
Total (95% CI) 157 170 0.70 [0.58, 0.86]
Total events: 72 (SSRI), 111 (Placebo)
Test for heterogeneity: Chi² = 1.15, df = 1 (P = 0.28), I² = 13.2%
Test for overall effect: Z = 3.44 (P = 0.0006)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 06 Non-responders (40% CY-BOCS)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 36/71 24/32 0.68 [0.50, 0.92]
Subtotal (95% CI) 71 32 0.68 [0.50, 0.92]
Total events: 36 (SSRI), 24 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 07 Non-responders (all)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 36/71 24/32 0.68 [0.50, 0.92]
Subtotal (95% CI) 71 32 0.68 [0.50, 0.92]
Total events: 36 (SSRI), 24 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
02 Fluvoxamine
Riddle 2001 33/57 46/63 0.79 [0.61, 1.04]
Subtotal (95% CI) 57 63 0.79 [0.61, 1.04]
Total events: 33 (SSRI), 46 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
03 Paroxetine
Geller 2004 39/100 65/107 0.64 [0.48, 0.86]
Subtotal (95% CI) 100 107 0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.003)
Total (95% CI) 228 202 0.70 [0.59, 0.83]
Total events: 108 (SSRI), 135 (Placebo)
Test for heterogeneity: Chi² = 1.24, df = 2 (P = 0.54), I² = 0%
Test for overall effect: Z = 4.18 (P < 0.0001)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 08 Non-responders (CGI Global Improvement)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Geller 2004 55/100 72/107 0.82 [0.66, 1.02]
Subtotal (95% CI) 100 107 0.82 [0.66, 1.02]
Total events: 55 (SSRI), 72 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.07)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 09 Remission (CY-BOCS < 11)
Study or sub-category
Sertraline n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline
POTS 2004 22/28 27/28 0.81 [0.66, 1.00]
Subtotal (95% CI) 28 28 0.81 [0.66, 1.00]
Total events: 22 (Sertraline), 27 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.05)
0.1 0.2 0.5 1 2 5 10
Favours Sertraline
Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 10 CY-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -9.50(9.20) 32 -5.20(7.40) -0.49 [-0.91, -0.07]
Liebowitz 2002 21 14.71(8.73) 22 18.55(11.44) -0.37 [-0.97, 0.23]
Riddle 1992 7 13.60(5.70) 6 14.80(7.00) -0.18 [-1.27, 0.92]
Subtotal (95% CI) 99 60 -0.43 [-0.76, -0.10]
Test for heterogeneity: Chi² = 0.33, df = 2 (P = 0.85), I² = 0%
Test for overall effect: Z = 2.53 (P = 0.01)
02 Fluvoxamine
Riddle 2001 57 18.20(8.60) 63 20.90(8.50) -0.31 [-0.67, 0.05]
Subtotal (95% CI) 57 63 -0.31 [-0.67, 0.05]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.09)
03 Sertraline
March 1998 92 -6.80(8.35) 95 -3.40(8.00) -0.41 [-0.70, -0.12]
POTS 2004 28 16.50(9.10) 28 21.50(5.40) -0.66 [-1.20, -0.12]
Subtotal (95% CI) 120 123 -0.47 [-0.72, -0.21]
Test for heterogeneity: Chi² = 0.61, df = 1 (P = 0.43), I² = 0%
Test for overall effect: Z = 3.60 (P = 0.0003)
04 Paroxetine
Geller 2004 94 -8.78(7.65) 102 -5.34(7.78) -0.44 [-0.73, -0.16]
Subtotal (95% CI) 94 102 -0.44 [-0.73, -0.16]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.002)
Total (95% CI) 370 348 -0.43 [-0.58, -0.28]
Test for heterogeneity: Chi² = 1.44, df = 6 (P = 0.96), I² = 0%
Test for overall effect: Z = 5.59 (P < 0.00001)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 11 NIMH-OC
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -3.10(3.00) 32 -1.30(2.20) -0.64 [-1.07, -0.22]
Liebowitz 2002 21 6.24(2.45) 22 7.18(2.75) -0.35 [-0.96, 0.25]
Subtotal (95% CI) 92 54 -0.55 [-0.89, -0.20]
Test for heterogeneity: Chi² = 0.59, df = 1 (P = 0.44), I² = 0%
Test for overall effect: Z = 3.07 (P = 0.002)
02 Fluvoxamine
Riddle 2001 57 7.50(3.20) 63 8.30(2.60) -0.27 [-0.63, 0.09]
Subtotal (95% CI) 57 63 -0.27 [-0.63, 0.09]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
03 Sertraline
March 1998 92 -2.20(2.78) 95 -1.30(2.63) -0.33 [-0.62, -0.04]
Subtotal (95% CI) 92 95 -0.33 [-0.62, -0.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.02)
Total (95% CI) 241 212 -0.38 [-0.57, -0.19]
Test for heterogeneity: Chi² = 1.91, df = 3 (P = 0.59), I² = 0%
Test for overall effect: Z = 3.93 (P < 0.0001)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Placebo

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 12 Child Obsessive Compulsive Impact Scale (Parent Version)



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 13 Leyton Obsessional Inventory (Child Version): interference



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 14 Leyton Obsessional Inventory (Child Version): resistance



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 15 Leyton Obsessional Inventory (Child Version): symptoms



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 16 Children's Depression Rating Scale (Revised Version)



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 17 Hamilton Rating Scale for Depression




Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 18 Depression (CDRS; HRSD)
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 21 9.14(6.56) 22 7.09(7.39) 0.29 [-0.31, 0.89]
Subtotal (95% CI) 21 22 0.29 [-0.31, 0.89]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
02 Fluvoxamine
Riddle 2001 57 27.40(8.00) 63 27.10(8.00) 0.04 [-0.32, 0.40]
Subtotal (95% CI) 57 63 0.04 [-0.32, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 78 85 0.10 [-0.20, 0.41]
Test for heterogeneity: Chi² = 0.49, df = 1 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.65 (P = 0.51)
-1 -0.5 0 0.5 1
Favours SSRI Favours placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 19 Multidimensional Anxiety Scale for Children
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -9.00(18.60) 32 -4.50(16.50) -0.25 [-0.67, 0.17]
Subtotal (95% CI) 71 32 -0.25 [-0.67, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
-1 -0.5 0 0.5 1
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 20 Revised Children's Manifest Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Riddle 1992 6 45.70(13.30) 5 40.20(16.90) 0.34 [-0.86, 1.53]
Subtotal (95% CI) 6 5 0.34 [-0.86, 1.53]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
-4 -2 0 2 4
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 21 Anxiety (MASC; RCMAS)
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -9.00(18.60) 32 -4.50(16.50) -0.25 [-0.67, 0.17]
Riddle 1992 6 45.70(13.30) 5 40.20(16.90) 0.34 [-0.86, 1.53]
Subtotal (95% CI) 77 37 -0.19 [-0.58, 0.21]
Test for heterogeneity: Chi² = 0.81, df = 1 (P = 0.37), I² = 0%
Test for overall effect: Z = 0.92 (P = 0.36)
-4 -2 0 2 4
Favours SSRI Favours placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 22 Children's Global Assessment Scale
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Riddle 1992 7 70.40(13.20) 6 62.00(8.40) 0.69 [-0.44, 1.83]
Subtotal (95% CI) 7 6 0.69 [-0.44, 1.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
-4 -2 0 2 4
Favours SSRI Favours Placebo

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 23 Systolic blood pressure - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	108.50(12.50)	95	107.60(10.60)		0.08 [-0.21, 0.36]
Subtotal (95% CI)	92		95			0.08 [-0.21, 0.36]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.53 (P = 0.60)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	108.10(12.10)	95	107.00(11.00)		0.09 [-0.19, 0.38]
Subtotal (95% CI)	92		95			0.09 [-0.19, 0.38]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.65 (P = 0.52)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	107.00(11.00)	95	107.40(10.60)		-0.04 [-0.32, 0.25]
Subtotal (95% CI)	92		95			-0.04 [-0.32, 0.25]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.25 (P = 0.80)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 24 Systolic blood pressure - standing

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	108.40(11.00)	95	107.40(10.90)		0.09 [-0.20, 0.38]
Subtotal (95% CI)	92		95			0.09 [-0.20, 0.38]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.62 (P = 0.53)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	106.20(11.40)	95	107.20(11.70)		-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95			-0.09 [-0.37, 0.20]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.59 (P = 0.56)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	105.80(10.80)	95	107.10(10.90)		-0.12 [-0.41, 0.17]
Subtotal (95% CI)	92		95			-0.12 [-0.41, 0.17]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.81 (P = 0.42)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 25 Diastolic blood pressure - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	64.80(8.50)	95	64.40(10.20)		0.04 [-0.24, 0.33]
Subtotal (95% CI)	92		95			0.04 [-0.24, 0.33]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.29 (P = 0.77)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	63.00(8.70)	95	63.80(9.40)		-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95			-0.09 [-0.37, 0.20]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.60 (P = 0.55)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	63.70(10.90)	95	64.50(8.80)		-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95			-0.08 [-0.37, 0.21]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.55 (P = 0.58)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 26 Diastolic blood pressure - standing

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	67.60(9.40)	95	67.70(10.60)		-0.01 [-0.30, 0.28]
Subtotal (95% CI)	92		95			-0.01 [-0.30, 0.28]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.07 (P = 0.95)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	67.20(10.60)	95	67.40(9.80)		-0.02 [-0.31, 0.27]
Subtotal (95% CI)	92		95			-0.02 [-0.31, 0.27]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.13 (P = 0.89)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	67.10(9.20)	95	67.80(8.90)		-0.08 [-0.36, 0.21]
Subtotal (95% CI)	92		95			-0.08 [-0.36, 0.21]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.53 (P = 0.60)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 27 Heart rate - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	75.40(12.70)	95	77.80(13.00)		-0.19 [-0.47, 0.10]
Subtotal (95% CI)	92		95			-0.19 [-0.47, 0.10]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.27 (P = 0.20)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	76.90(11.50)	95	78.10(11.80)		-0.10 [-0.39, 0.18]
Subtotal (95% CI)	92		95			-0.10 [-0.39, 0.18]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.70 (P = 0.48)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	77.30(9.80)	95	78.40(13.00)		-0.09 [-0.38, 0.19]
Subtotal (95% CI)	92		95			-0.09 [-0.38, 0.19]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.65 (P = 0.52)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 28 Heart rate - standing

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	81.40(13.90)	95	86.10(13.30)		-0.34 [-0.63, -0.06]
Subtotal (95% CI)	92		95			-0.34 [-0.63, -0.06]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.34 (P = 0.02)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	83.90(13.80)	95	84.50(12.00)		-0.05 [-0.33, 0.24]
Subtotal (95% CI)	92		95			-0.05 [-0.33, 0.24]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.32 (P = 0.75)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	85.10(12.10)	95	86.20(15.30)		-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95			-0.08 [-0.37, 0.21]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.54 (P = 0.59)						




Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 29 Suicidality (Columbia reclassification - "Outcome 3: definitive suicidal behaviour/ ideation")
Study or sub-category
Treatment n/N
Control n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 1/71 0/32 1.38 [0.06, 32.87]
Subtotal (95% CI) 71 32 1.38 [0.06, 32.87]
Total events: 1 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
02 Fluvoxamine
Riddle 2001 2/57 0/63 5.52 [0.27, 112.55]
Subtotal (95% CI) 57 63 5.52 [0.27, 112.55]
Total events: 2 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
03 Paroxetine
Geller 2004 1/99 0/107 3.24 [0.13, 78.62]
Subtotal (95% CI) 99 107 3.24 [0.13, 78.62]
Total events: 1 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
04 Sertraline
March 1998 0/92 1/95 0.34 [0.01, 8.34]
Subtotal (95% CI) 92 95 0.34 [0.01, 8.34]
Total events: 0 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 319 297 1.81 [0.46, 7.13]
Total events: 4 (Treatment), 1 (Control)
Test for heterogeneity: Chi² = 1.72, df = 3 (P = 0.63), I² = 0%
Test for overall effect: Z = 0.84 (P = 0.40)
0.01 0.1 1 10 100
Favours treatment Favours control


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 01 Adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 3/11 0/7 4.67 [0.28, 78.68]
Subtotal (95% CI) 11 7 4.67 [0.28, 78.68]
Total events: 3 (SSRI), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
0.01 0.1 1 10 100
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 02 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 1/12 0/7 1.85 [0.09, 40.05]
Subtotal (95% CI) 1/12 0/7 1.85 [0.09, 40.05]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
0.01 0.1 1 10 100
Favours SSRI Favours Placebo

Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 03 CY-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Liebowitz 2002	11	5.64(5.41)	7	11.43(11.12)		-0.69 [-1.67, 0.30]
Subtotal (95% CI)	11		7			-0.69 [-1.67, 0.30]

Test for heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)



Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 04 NIMH-OC

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Liebowitz 2002	11	3.73(1.74)	7	5.43(3.10)		-0.69 [-1.67, 0.29]
Subtotal (95% CI)	11		7			-0.69 [-1.67, 0.29]

Test for heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)



Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 05 Child Obsessive Compulsive Impact Scale (Parent version)

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Liebowitz 2002	11	23.00(20.57)	7	49.29(32.70)		-0.97 [-1.98, 0.04]
Subtotal (95% CI)	11		7			-0.97 [-1.98, 0.04]

Test for heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.06)



Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 06 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine						
Liebowitz 2002	11	4.64(6.14)	7	7.14(5.24)		-0.41 [-1.37, 0.55]
Subtotal (95% CI)	11		7			-0.41 [-1.37, 0.55]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)

Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 01 Adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% CI	RR (fixed) 95% CI
Carpenter 1999	73/95	80/98		0.94 [0.81, 1.09]
Total (95% CI)	95	98		0.94 [0.81, 1.09]

Total events: 73 (Paroxetine), 80 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 02 Serious adverse events



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 03 Leaving the study early



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 04 Leaving the study early due to adverse events



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 05 Non-responders (25% CY-BOCS)



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 06 Non-responders (CGI Global Improvement < "much improved")













Clomipramine (OCD, children)

Review: OCD children: Clomipramine
Comparison: 01 Clomipramine vs placebo
Outcome: 01 Leaving study early



Review: OCD children: Clomipramine
Comparison: 01 Clomipramine vs placebo
Outcome: 02 Leaving study early due to adverse effects



Review: OCD children: Clomipramine
Comparison: 01 Clomipramine vs placebo
Outcome: 03 Y-BOCS



Review: OCD children: Clomipramine
Comparison: 01 Clomipramine vs placebo
Outcome: 04 NIMH-OC



Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 01 Leaving study early



Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 02 Relapse (Physician's Relapse Scale)



Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive



Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 04 NIMH-OC



Pharmacological (BDD)

Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 01 Adverse effects



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 02 Leaving study early



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 03 Leaving study early due to adverse effects



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 04 Non-responders



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 05 BDD-YBOCS



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 06 BDD-NIMH



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 07 Hamilton Rating Scale for Depression



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 08 Global Assessment of Functioning Scale



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 09 Social & Occupational Functioning Scale



Review: BDD: pharmacological interventions
Comparison: 02 Clomipramine v Desipramine
Outcome: 01 BDD-YBOCS at 8 weeks



Review: BDD: pharmacological interventions
Comparison: 02 Clomipramine v Desipramine
Outcome: 02 NIMH-BDD at 8 weeks




Review: BDD: pharmacological interventions
Comparison: 02 Clomipramine v Desipramine
Outcome: 03 HAM-D at 8 weeks
Study or sub-category
Clomipramine N Mean (SD)
Desipramine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Hollander 1999 12 9.42(7.89) 11 14.64(5.61) -0.73 [-1.58, 0.12]
Total (95% CI) 12 11 -0.73 [-1.58, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.09)
-4 -2 0 2 4
Favours CMI Favours DMI


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 01 Non-responders (Y-BOCS 30%)
Study or sub-category
Pimozide n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Phillips_in press 9/11 14/17 0.99 [0.70, 1.42]
Total (95% CI) 9/11 14/17 0.99 [0.70, 1.42]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
0.2 0.5 1 2 5
Favours Pimozide Favours Placebo


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 02 Leaving the study early
Study or sub-category
Pimozide n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Phillips_in press 6/11 13/17 0.71 [0.39, 1.30]
Total (95% CI) 6/11 13/17 0.71 [0.39, 1.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
0.2 0.5 1 2 5
Favours Pimozide Favours Placebo


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 03 Y-BOCS
Study or sub-category
Pimozide N Mean (SD)
Placebo N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Phillips_in press 11 23.90(6.60) 17 28.00(7.80) -4.10 [-9.48, 1.28]
Total (95% CI) 11 17 -4.10 [-9.48, 1.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
-10 -5 0 5 10
Favours Pimozide Favours Placebo


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 04 Brown Assessment of Beliefs Scale
Study or sub-category
Pimozide N Mean (SD)
Placebo N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Phillips_in press 11 13.50(7.30) 17 17.20(6.00) -3.70 [-8.87, 1.47]
Total (95% CI) 11 17 -3.70 [-8.87, 1.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
-10 -5 0 5 10
Favours Pimozide Favours Placebo

Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 05 Hamilton Depression Rating Scale



Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 06 Brief Psychiatric Rating Scale